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THE ROLE OF G PROTEIN-COUPLED ESTROGEN RECEPTOR IN
VASCULAR FUNCTION AND HYPERTENSION
by
Natalie C. Fredette
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Doctorate of Philosophy, Biomedical Sciences

ABSTRACT:
Regulation of arterial tone relies heavily on molecular crosstalk between
endothelial and smooth muscle cells. Although it has been demonstrated that
estrogen (E2) exerts protective effects against cardiovascular disease (CVD),
the exact mechanisms and balance of E2 signaling in endothelial and smooth
muscle cells remain unresolved. Here we characterize the G protein-coupled
estrogen receptor (GPER) in the vasculature by elucidating its pathway in
endothelial nitric oxide (NO) production and vascular smooth muscle
maintenance of reactive oxygen species (ROS) by NADPH oxidases (NOX).
NO is thought of as a vasoprotective entity, while the overproduction of ROS by
NOX can lead to vascular dysfunction. These two forces counteract each other
to maintain arterial tone, and understanding their mediation by GPER will
provide significant insights in sex differences in vascular function.
In endothelial cells, we demonstrated that GPER activation induces
phosphorylation of eNOS at ser1179, and contributes to ER-dependent NO
production. Inhibition of GPER through pharmacologic antagonism (G36) or
genomic deletion (GPER KO) reduced NO production and vasorelaxation to
viii

E2. We also found that NO production by selective estrogen receptor modifiers
and downregulators (SERMs/SERDs), known to antagonize classic ERs and
agonize GPER, was only partially abrogated by GPER inhibition, suggesting
that there may be E2- independent targeting effects by these compounds.
In the smooth muscle we were surprised to find that the arteries of GPER
KO animals exhibited a reduced contraction response to Ang II. We
characterized a novel pathway in which GPER mediates genomic expression
of the NOX1 subunit in smooth muscle cells. Critically, we report that GPER
inhibition or deletion reduces or blocks the hypertensive response to Ang II in
mice.
Taken together, these data describe a counterintuitive paradigm in which
GPER signaling is important for E2-mediated NO production at the
endothelium through acute eNOS activation, but conversely is involved in ROS
generation at the smooth muscle though expression of NOX1. In lieu of the
conflicting CVD reported for E2 replacement in post-menopausal women, we
propose that the signaling pathway(s) of GPER may increase ROS production
through smooth muscle NOX1 expression, which may override endothelial NO
production, resulting in vascular dysfunction.
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CHAPTER 1
INTRODUCTION
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1.1 Estrogen Synthesis & Biochemistry:
Estrogen is a steroid hormone synthesized in the ovaries of sexually
mature females, and in the testes and adrenal glands of males. Estrogen is
also synthesized at comparatively lower levels in peripheral tissues of both
sexes, such as adipose, vascular endothelium and liver by the aromatase
enzyme. Estrogen is synthesized through a multi-step process (Fig 1.1). First,
cholesterol undergoes a multistep conversion into the androgen intermediate
adrostenedione. Adrostenedione is converted to testosterone, which is then
converted by the cytochrome P450 enzyme aromatase into estrone. Estrone
undergoes a hydroxyl addition by the enzyme 17β HSD to become 17β
estradiol. There are three naturally occurring forms of estrogen: estrone (E1),
estradiol (E2), and estriol (E3), which are named based on their number of
hydroxyl groups (1, 2 or 3, respectively) (Fig 1.2). The predominantly active
form of estrogen is 17β-estradiol, which has a second hydroxyl group located
at the beta position of the 17th carbon, and will be referred to in this thesis as
E2.
The ovaries begin to synthesize estrogen around 12-15 years of age and
continue until the 5th or 6th decade of life. Aromatase continues to synthesize
estrogen from testosterone at low levels in both sexes throughout an
individual’s life. In particular, low levels of E2 are secreted by the adipose
tissue. The primary form of estrogen in post-menopausal women is the
metabolite estrone (1). Circulating E2 has a half-life of approximately 3-10
hours in women and is metabolized in the liver by cytochrome p450 (CYP)
2

enzymes into the less metabolically active estrone and estriol, which are
passed in urinary excretion. Small amounts of estriol are reabsorped by the
liver into circulation, which partly contributes to basal estrogen levels.
E2 was originally described as the primary signaling molecule of sexual
maturation by Doisey et al. in 1923 (2). Doisey and colleagues crystallized
purified E2 from rat uterus, and reported that crystallized E2 induced
morphological changes in reproductive tissues associated with sexual maturity,
such as increased uterine wet weight, thickening of the vaginal wall, and
ovulation in rodents.
In circulation, E2 molecules are bound to albumin and globulin with
approximately 2 to 2.5% in an unbound or “biologically active” state. In
females, detectable serum E2 levels fluctuate with the menstrual cycle. Serum
concentrations of E2 typically range from 100-200 pM prior to cycling (follicular
phase), and peak at approximately 1 nM in the preovulatory phase. E2 levels
peak a second time post-ovulation (luteal phase) at concentrations up to 500
pM. Post-menopausal E2 serum levels typically range from 30 to 100 pM. In
sexually mature males, plasma E2 levels range from 50 to 100 pM, similar to
post-menopausal women. In females, reproduction-related functions of E2
include ovulation, endometrial development, breast and milk duct development,
as well as uterine and vaginal wall growth. In males, reproductive functions of
E2 include development of testes and epididymis as well as spermatogenesis
and sperm cell maturation in these tissues. In non-reproductive tissues, E2
has been implicated in osteocyte activity for bone health, brain development
3

and function, immune cell activation, production of clotting factors, adipose
tissue activation and metabolism, as well as multiple functions in
cardiovascular tissues, which will be a focus topic of this thesis.
1.2 Estrogen Receptors and Signaling
Experiments using tritiated E2 uncovered a specific binding pattern within
reproductive tissues (particularly the uterus), leading to the description of the
first “estrogen receptor” in 1967 by Jensen et al. (3) (4). These experiments
suggested that the effects of circulating E2 are mediated by its interaction with
a specific steroid receptor. Soon after, the isolation of a macromolecule from
the human uterus with specific binding to E2 was reported by McGuire et al. in
1972 (5). Since these initial reports, almost 40,000 studies have characterized
the structure, localization and function of these receptors.
1.2.1 Receptor structure and localization:
There are three primary receptors now accepted as mediating estrogen’s
physiologic effects: estrogen receptor alpha (ERα), estrogen receptor beta
(ERβ), and the more recently described G protein-coupled estrogen receptor
(GPER). For over 20 years only one estrogen receptor (ER) was known, until
the discovery of a second homologous receptor in rat prostate in 1996 (6).
These receptors were ultimately named ERα and ERβ, respectively. ERα and
ERβ share a 58% homology within the ligand binding domain and 96%
homology in the DNA binding domain (7-9). The third estrogen receptor, now
named G protein-coupled estrogen receptor GPER (formerly GPR30) was
4

cloned from shear stress-stimulated endothelial cells and breast cancer cell
lines in the late 1990s. Its signaling activities were described by several
laboratories in the early 2000s (10, 11). Expression of ERα and GPER has
been reported in multiple tissues and cell types including breast, uterus and
endometrium, adipose, kidney, brain, heart, immune cells and vascular tissues
with various physiologic effects (12).
Like other soluble steroid receptors, ERα and ERβ lack a plasma
membrane domain and reside predominantly in the nucleus and cytoplasm.
The lipophilic nature of its cholesterol-derived ligand E2 allows diffusion of E2
across plasma and other cellular membranes. The structure of ERα/β consists
of 5 domains (Fig 1.3). The activation function 1 “AF-1” A/B domain is located
at the amino terminus and is responsible for binding co-factors and other
proteins. The C domain is responsible for DNA binding and the D domain or
“hinge” domain provides flexibility of the receptor, allowing conformational
changes upon ligand interaction. The E domain contains the ligand (E2)
binding domain, and the AF2 F domain at the carboxyl terminus binds
transcriptional co-factors in a ligand-dependent manner. Within each of these
domains, multiple post-translational modifications such as phosphorylation and
palmitoylation (13) (14) regulate trafficking and signaling in a tissue-specific
manner (15) (16). Palmitoylation targets a small proportion of ERs to the
plasma membrane to scaffold with caveolin-1 (17) (18), whereas
phosphorylation of ERα can induce ligand-independent activation.

5

1.2.2 Signaling pathways: genomic and rapid
The first described and most studied signaling pathway of ERs is the
“classical” or “genomic” pathway (Fig 1.4 A). Upon ligand binding, ERs shed
Heat shock protein (HSP) and dimerize with a second ER as a homo or hetero
dimers (α/α, β/β, or α/β). The dimerized unit can then bind to multiple
transcription or co-factors, depending on cell and tissue type. Three general
mechanisms of genomic activation have been described. In “direct activation”,
ligand-activated, dimerized ERs bind DNA directly to estrogen response
elements (EREs) as a dimer via the C domain. In the second, “indirect
activation” (or “tethered activation”) mechanism, ligand-activated dimerized
ERs binds indirectly as a complex with other transcriptional co-factors at other
(non-ERE) gene promoters (19). The third mechanism of ER binding is ligandindependent, where kinases such as MAPK/ERK phosphorylate ERα in the
absence of E2 binding, resulting in receptor binding to EREs and other
promoter regions. Co-factor recruitment by ERs is tissue and cell type-specific,
depending on the molecular cues and post-translational modifications (16) (12).
In contrast to these now classic genomic signaling activities, early studies
by Szego et al. reported increases in uterine cyclic AMP (cAMP)
concentrations within minutes of E2 treatment (20). Szego et al. followed these
functional studies with reports identifying estrogen binding to isolated plasma
membranes of the uterine endometrium (21). These rapid cAMP increases in
response to E2 were later confirmed in vascular tissues treated with E2 (22,
23). Such reports indicated a role for rapid signaling induced by E2, and
6

suggested that ERs were functionally diverse in mediating both genomic and
rapid signaling responses. Additional rapid effects mediated by E2 have been
demonstrated in multiple cell types, including EGF release, ERK and Akt
activation, calcium mobilization and vascular nitric oxide production, the latter
in vascular endothelial cells (24, 25) (Fig 1.4.B). One mechanism of rapid
signaling by ERs has been proposed to occur through a small subpopulation of
membrane-bound ERs (26) (mERs). Membrane association of ERs requires
post-transcriptional palmitoylation within the E domain and tethering to the
membrane in caveolae lipid rafts by the scaffolding protein Caveolin 1 (14, 27,
28) (29, 30). Ligand activated mERα subsequently activates heterotrimeric G
proteins, such as Gq, which in turn activate PLC to cleave PIP3 into IP3 and
DAG downstream targets, or Gi/s proteins that regulate adenylyl cyclase
activity to decrease (αi) or increase (αs) cAMP. Studies with pertussis toxin, a
Gi protein inhibitor, have been shown to abrogate ERα rapid signaling,
revealing the role of this G protein in estrogen signaling (24, 31).
1.3 GPER discovery & mechanisms:
The extensive cloning of GPCRs in the late 1990s yielded a plethora of
receptors with no known ligand, resulting in their designation as orphan
receptors, and heralded decades of research aimed at identifying
endogenous ligands for these receptors and describing their physiologic
functions (16180917 9884064). The orphan GPCR ‘GPR30’ was cloned from
human endothelial cells exposed to shear stress (among other sources),
implicating a function in vascular tissues (32). Soon after its cloning, studies
7

by Filardo et al. characterized GPR30 as a receptor that mediated rapid
signaling in response to E2 (33) (10). This was based on the observation of
rapid ERK1/2 phosphorylation in response to E2 in SKBr3 cells, a GPR30expressing breast cancer cell line that lacks expression of both ERα and
ERβ, as well as in MDA-MB-231 breast cancer cells when transfected with
GPR30 (34). However, these early reports of rapid estrogen-mediated
signaling in GPR30-expressing cells did not establish commensurate binding
of E2. Only in 2005 did separate studies by Revankar et al. and Thomas et
al. report specific E2 binding in GPR30-expressing cells. Experiments by
Thomas et al. utilized tritiated E2 in SKBr3 (ERα/β-negative, GPER-positive)
cells, and in HEK293 cells (GPER/ERα/β-negative) transfected with GPR30,
and observed tritiated E2 binding only in GPR30-expressing cells. They
calculated a binding affinity of E2 for GPER of 3.3 nM, suggesting E2 as a
ligand for GPR30.
In a study using transfection of a GFP-GPR30 fusion protein into COS7
cells (GPER/ERα/β-negative), Revankar et al. demonstrated that GPER
predominantly localized to an intracellular tubuloreticular network, including
the endoplasmic reticulum and Golgi apparatus, with negligible expression at
the plasma membrane or in the nucleus (11). A novel Alexa633-conjugated
E2 compound was found to colocalize with GFP-fused GPER in transfected
COS7 cells and demonstrated a binding affinity of 6 nM, similar to the
experimental values reported by Thomas et al. in HEK293 cells. These
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reports provided convincing evidence that the orphan receptor GPR30 was
likely a receptor for binding and mediating the rapid signaling effects of E2.
Filardo and colleagues as well as others (34) (35) (11) first described rapid
signaling of GPER via EGFR transactivation by employing a series of inhibitors
to investigate increased phosphorylated ERK levels in MCF7 (ERα+/GPER+)
and SKBr3 (ERα-/GPER+) breast cancer cell lines (33). This increase was
abrogated by the ERK inhibitor PD98059 and the EGFR inhibitor AG1478, and
was also inhibited by pertussis toxin, an inhibitor of the Gαi proteins (36).
Inhibition of c-Src kinase signaling using PP2 also blocked GPER-mediated
ERK1/2 phosphorylation (37). Furthermore, neutralizing antibodies to HB-EGF
also blocked GPER-mediated ERK1/2 phosphorylation. Thus, the following
mechanism of GPER in rapid cell signaling was proposed (Fig 1.5). First,
ligand binding of E2 to GPER leads to activation of G protein subunits and
phosphorylation of c-Src, which in turn activates matrix metalloproteases
(MMP). MMPs cleave extracellular pro-heparin-binding epidermal growth factor
(pro HB-EGF) into it its activated form HB-EGF. HB-EGF then binds with the
EGFR receptor tyrosine kinase at the plasma membrane, which initiates a
cascade of multiple enzyme activation pathways, including most notably
ERK1/2 phosphorylation, PI3K/AKT activation and/or c-Src activation. GPER
has also been shown to activate adenylyl cyclase (AC) and increase cAMP
through Gαs, which was downregulated ERK1/2 phosphorylation (38).
Characterization of this additional GPER mechanism suggests that there is a
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tight regulation of ERK1/2 activity by GPER to prevent overstimulation of
adenylyl cyclase.
Another downstream target of cross-activated EGFR is PI3K/AKT. Our
laboratory first reported that GPER activation by E2 also induces PI3K
signaling, which results in the production of PIP3 and the recruitment and
activation of AKT. Experiments from our laboratory utilized the monomeric red
fluorescent protein (mRFP)-fused PH domain of AKT (mRFP-PH) to assess
PIP3 production following GPER activation with E2 or 4-hydroxy tamoxifen
(4OHT) in COS7 cells transfected with mRFP-PH and GFP-fused GPER.
These experiments demonstrated that GPER activation resulted in
translocation of mRFP-PH to the nucleus, suggesting production or at least
accumulation of PIP3 in the nucleus following GPER activation. GPERmediated nuclear translocation of mRFP-PH was blocked by LY294004, an
inhibitor of PI3K/AKT signaling, demonstrating the involvement of PI3K in this
process. Finally, intracellular calcium increases in response to GPER
activation have been reported in cells exogenously and endogenously
expressing GPER (34) (39) (40) (41). Experiments revealed that GPER
activation with E2 resulted in increased intracellular calcium levels using the
calcium-sensitive dye Indo1-AM in GPER-transfected COS7 cells. Calcium
increases by GPER were abrogated both by EGFR inhibitor AG1478 and by
the Gi protein inhibitor pertussis toxin (33) (36), indicating GPER increases
intracellular calcium through Gαi and EGFR signaling pathways. Taken
together, these data demonstrated a novel non-classical estrogen receptor
10

(GPER) can mediate several forms of rapid estrogen signaling through a G
protein-coupled mechanism, resulting in EGFR transactivation for pathways
promoting ERK1/2 activation, Ca2+ increase, and PI3K/AKT activation (42).
In addition to rapid signaling of GPER, several genomic effects of GPER
have also been described. Activation of GPER has been linked to increased
expression of cell cycle regulation proteins such as cyclin A, cyclin D1, cyclin
E, and early growth response-1 factor (43) (44) (45) (46). Most of these
genomic influences are mediated by the GPER pathway components EGFR,
ERK and PI3K. Interestingly, a direct genomic mechanism of GPER/EGFR
complex binding to the promoter region of cyclinD1 gene has also been
reported (46). A mechanism of GPER nuclear localization has been suggested
to occur through the nuclear trafficking protein importin (47). GPER-mediated
genomic signaling has been specifically implicated in vascular tissues and
targets, including early studies in rat aortic smooth muscle showing that E2
treatment leads to increased expression of c-fos in a GPER-dependent
manner, (45), and increased expression of vascular endothelial growth factor
(VEGF). It should be noted that the delineation of genomic and rapid signaling
effects may be considered arbitrary, since rapid activation of secondary
kinases can initiate downstream transcription factor activation and changes in
gene expression, making these actions inseparably linked. In recent years,
GPER signaling has been studied in multiple systems and pathologies using
uniquely designed synthetic compounds.
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1.4 GPER-targeting compounds:
To advance investigations into GPER-mediated cell signaling and its
physiological consequences, our laboratory with collaborators at New Mexico
State University developed a GPER-specific agonist (G-1) and two antagonists
(G15 and G36)(48) (49) (Fig.1.5). The GPER specific agonist G-1 is based on
a tetrahydro-3H-cyclopentoquinolone (50, 51) structure with an ethanone
moiety that may be involved in binding to GPER within the ligand pocket and
may provide for steric hindrance limiting cross reactivity with ERα and β (50).
The binding affinity of G-1 to GPER was determined to be approximately 10 nM
(49). G-1 specificity for GPER is approximately 10,000-fold higher than for
ERα/β. Weak biological effects of G-1 binding towards ERα were observed at
concentrations of 10 μM, with the transcriptional activity through ERα being
less than that observed at 10 pM E2 (49). Studies using G-1 have
demonstrated a variety of GPER-mediated effects, including endometrial and
breast epithelial cell proliferation, modulation of immune cell activity, and
vasodilaton in epicardial coronary arteries (52) (53) (54).
Two GPER antagonists have been developed, G15 and G36 (Fig 1.6).
The G15 compound lacks the ethanone moiety, but still binds to GPER with an
affinity similar to G-1 (~2-fold reduced). In vivo administration of G15 in mice
resulted in reduced uterine epithelial cell proliferation in vivo and the inhibition
of PI3K-mediated activation by E2 (50) (42). To improve antagonist specificity,
G36 was designed with the replacement of an isopropyl moiety for the
ethanone group of the original G-1 compound. It was hypothesized that this
12

modification increased steric inhibition of G36 with ERα/β, thereby improving
the selectivity for GPER (51).
Numerous studies employing G-1 and G-15/G36 describe GPER-specific
signaling effects in the absence of ER signaling (52) (54) (50) (55). These
studies also corroborate the efficacy of GPER targeting compounds to treat
multiple pathologies such as breast or endometrial cancer, diabetes,
osteoporosis, cardiac remodeling, hypertension and stroke (56) (57). Section
1.6 will discuss some of the discoveries of GPER signaling in vascular function
using these GPER-targeting compounds.
1.5 SERMs and SERDs: GPER and ER Targeting with pharmacologic
compounds:
Multiple pharmacologic tools have been developed to study estrogen
receptor signaling. Some of these compounds are used in the clinic today to
treat pathologies involving E2 signaling such as breast cancer and
osteoporosis (58) (59). One of the earliest examples of pharmacologic
targeting of ERs was the synthetic estrogen ethinyl estradiol, a long-acting form
of E2 approved by the FDA in 1943. This synthetic estrogen is prescribed in
several types of birth control pills. Ethinyl estradiol constitutively activates ERα
to propagate a negative feedback loop to the hypothalamus/pituitary gland
axis, which in turn downregulates the production of follicle stimulating hormone
and luteinizing hormone (FSH and LH), thereby preventing ovulation.
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Since the implementation of ethinyl estradiol, multiple additional
pharmacologic ER-targeting compounds have been described. These
compounds are classified according to their ability to agonize or antagonize
signaling of the classic ERα/β, but not by their effects on GPER signaling,
which can vary. Compounds termed selective estrogen receptor modifiers
(SERMS) bind estrogen receptors to induce either activation or inhibition of
estrogen receptors in a tissue-specific manner (60) (61) (62) (63) (64), whereas
selective estrogen receptor downregulators (SERDs) work either by direct
antagonism of an ER, or by long-term downregulation by targeting ERs for
proteosomal degradation (65). SERMs and SERDs of clinical relevance
include tamoxifen, raloxifene, and ICI 182,780 (fluvestrant), which are utilized
in this thesis (Fig 1.7).
Tamoxifen is a SERM of particular interest for its contrasting ER/GPER
effects, and also because it is used in the clinic as a chemotherapeutic in
breast cancer (52, 66) and yet based on its vascular effects could also
potentially be utilized as a therapeutic in vascular dysfunction. The
metabolically active metabolite of tamoxifen is 4-hydroxytamoxifen (4-OHT),
which is produced in the liver. Tamoxifen inhibits ERα activity by competitive
antagonism, competing with E2 for the receptor binding site but not activating
it. Studies have described a positive correlation of tamoxifen and improved
vascular function, such as increased endothelial function (67). Tamoxifen has
also been shown to increase cyclin E (a cell cycle regulator) activation in a
GPER-dependent manner in breast cancer cell lines (68). Tamoxifen-mediated
14

activation of GPER also results in PI3K/AKT activation and intracellular calcium
mobilization(69, 70) (71). It has been hypothesized that tamoxifen may
improve endothelial function by increasing endothelial cell calcium to mediate
calcium-dependent eNOS activation and NO production (72). 4-hydroxy
tamoxifen (4-OHT) has been demonstrated to increase migration of the breast
cancer cell lines MCF-7 (ERα+, GPER+) and SKBr3 (ERα-, GPER+) in a
GPER-dependent manner through EGFR activation that induces cleavage of
cyclin E (68) (73). Tamoxifen-induced cleavage of cyclin E into its activated
was blocked by both GPER inhibition (siRNA), and by EGFR inhibitor AG1478,
demonstrating the roles of GPER and EGFR in this pathway. Finally,
tamoxifen metabolite (4OHT) has also been shown to induce cell migration
through GPER by activation of focal adhesion kinases (FAK) in endometrial
cancer cell lines expressing or lacking ERα (Ishikawa and RL95-2,
respectively) (74). Pretreatment of Ishikawa and RL95-2 cells with siRNA
targeting GPER reduced tamoxifen-induced FAK phosphorylation (Y397), as
did pharmacologic inhibition of the GPER signaling intermediates PI3K/AKT
(LY294002) and ERK1/2 (PD98059).
Raloxifene is another SERM compound that has been shown to alter both
genomic and rapid signaling of ERα/β and GPER (62). Studies have
demonstrated that raloxifene has anti-estrogenic effects in reducing breast and
endometrial cancers by promoting apoptosis (75), and pro-estrogenic effects in
bone health by improving osteoblast proliferation (76) (73) (77) and improved
dopamine neuron function by activating GPER for increased AKT function (78).
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GPER has been shown to mediate multiple additional effects of raloxifene. For
example, raloxifene-mediated increases in MAPK activity and the resulting cell
proliferation were blocked by GPER-targeting siRNA (79). Raloxifene
treatment of the osteocyte cell line hFOB resulted in increased proliferation,
and this proliferation was abrogated in the absence of GPER signaling using
GPER inhibitors or GPER-targeting siRNA (79). Raloxifene has also been
reported to have pro-estrogenic effects on the vasculature by improving
endothelial function by reducing oxidative stress (80), and improving flowmediated dilation in women (62). Raloxifene has also been shown to increase
nitric oxide (NO) levels in aorta in both ovarectomized and intact rats (81) and
to induce vasodilation in pressurized arteries (82) and in vivo (83).
Other pharmacologic compounds function as selective estrogen receptor
downregulators or SERDs. As SERDs were characterized and designed prior
to the discovery of GPER, the nomenclature of SERDs applies strictly to their
effects on ERα/β regardless of their effects on GPER. SERD compounds,
such as ICI 182,780, work either by direct antagonism of ERs, or by long-term
downregulation by targeting ERs for proteosomal degradation (65). Most
SERDs target only classic ERs for long-term downregulation while having
either no effect or even agonistic effects on GPER, which is the case with ICI
182,780. Studies by Meyer et al. demonstrated that ICI 182,780 induces
vasorelaxation in human coronary arteries, likely through agonism of GPER
(54). Such divergent receptor actions lend to complex effects of these SERMS
and SERDs, which are still not fully understood (71).
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1.6 A focus on estrogen and the vasculature:
Although the majority of biomedical studies involving E2 address cancers
of the reproductive system, there have been numerous studies attributing
estrogen action to cardiovascular function and dysfunction. Consistent and
dynamic maintenance of arterial blood pressure is vital for adequate perfusion
of peripheral tissues and organs and for healthy heart function. An increase in
the incidence of cardiovascular disease (CVD) is observed in post-menopausal
women, and protection against CVD in pre-menopasual women (lower
incidence vs. men) is attributed to ovarian hormone signaling. Given these
observations, it is vital to understand the contribution of estrogen to these
functions. Elucidating the role of estrogenic signaling in cardiovascular
function and disease represents a significant progression in the fields of both
vascular biology and gender medicine.
Clinical observations have documented a sex-dependent difference in the
resistance to cardiovascular disease (CVD), in which pre-menopausal women
have decreased incidence of CVD compared to men (where CVD positively
correlates with age) until the onset of menopause, when the risk of CVD in
women increases and with time approaches that of men (84) (85) (86). These
observations suggested a protective effect of female ovarian hormones,
specifically E2, against CVD. In recent years, advances in the field of E2
signaling mechanisms in cardiovascular tissues have yielded complex yet
intriguing results.
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1.6.1 The structure and functions vasculature:
The vascular system is made up of arteries, capillaries, and veins. The
arteries shuttle oxygenated blood from the heart to peripheral tissue; the
capillaries facilitate the exchange of gases between blood and target peripheral
tissues, and the veins bring deoxygenated blood back to the heart for
rexoygenation in the lungs. While regulation from the CNS and peripheral
nervous system is important, this thesis focuses on the dynamics of endothelial
and smooth muscle cross-talk in regulating vasomotor tone in the artery. The
artery is made up of an endothelial layer forming the luminal surface, smooth
muscle at the medial layer, and a surrounding layer of fibroblast adventitia and
perivascular fat.
1.6.2 The endothelium:
The endothelium is a single cell layer forming the luminal surface of the
vessel. Early studies described the endothelium as a simple selectively
permeable barrier for various hormones, peptides and immune cells carried in
the blood. Later on, the endothelium was found to be a dynamic signaling
tissue responsible for the production of multiple paracrine signaling molecules
such as NO, prostacyclin, coagulation factors and inflammatory signaling.
Studies by Nobel laureate Robert Furchgott in the 1980s elegantly
demonstrated the existence of an endothelium-derived relaxation factor
(EDRF) that acted upon adjacent smooth muscle cells to mediate vasodilation.
In these experiments, rabbit aorta segments with an intact endothelium were
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able to dilate to acetylcholine, but arteries that had been denuded of the
endothelium could not, suggesting the endothelium was necessary for
mediating smooth muscle relaxation, possibly through the secretion of a
relaxation factor to act on adjacent smooth muscle. Soon after Furchgott’s
report, EDRF was found to be a diffusible compound from the endothelium to
the smooth muscle in a series of experiments by Busse and Bassange (87,
88). Cannulation of arteries in series showed that arteries denuded of
endothelium were unable to dilate independently to acetylcholine, but were
able to dilate if an endothelium intact artery was cannulated upstream, acting
as a “donor vessel” to deliver EDRF to the downstream denuded artery to
induce vasorelaxation. This diffusible EDRF was subsequently demonstrated
to possess a short half-life of 20 to 30 seconds (88). In these studies, a
surrogate endothelial source (microbeads covered with bovine endothelial
cells) was stimulated with ATP and the perfusate traveled downstream to a
cannulated rabbit femoral artery. In some cases, a delay coil was added to
increase transit time from the surrogate endothelium to the downstream artery.
These studies demonstrated an inverse relationship of transit time for perfusate
and the vasodilation response of the downstream endothelium-denuded artery
(i.e., longer transit time resulted in decreased dilation). EDRF was identified as
nitric oxide (NO) by a number of groups, although its identity was debated for
several years (89, 90).
Another class of endothelium-derived relaxation factors, the prostanoids,
was described by De Mey and Vanhoutte in the 1980s (91) (92, 93).
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Prostanoids are lipophilic metabolites synthesized from arachidonic acids by
cyclooxygenase (COX1/2) enzymes. Prostanoid metabolite specificity
depends on the post-COX cleavage enzymes, which generate prostaglandins,
thromboxanes, or prostacyclins. Endothelium-derived contraction factors
(EDCFs) include thromboxane A2 (TBA2) and multiple types of prostaglandins
(PGFs, PGHs). Thromboxanes and prostaglandins act upon smooth muscle
TP receptors at the adjacent VSMCs in increase cyclic GMP formation and
PKG activity to induce vasoconstriction and vasomotor tone (94) (95).
Prostaglandin F2α (PGF2α) is an EDCF that is commonly used in experimental
settings to precontract arteries to test E2-mediated vasorelaxation.
Prostaclyclin (PGI2) is an endothelium-derived vasorelaxing factor that acts
upon VSMC prostacyclin receptors to induce vasorelaxation through AC
activation and cAMP increase (96, 97) (97) .
Taken together, studies from the 1980s onward have demonstrated the
diverse functional importance of the endothelium in maintaining vasotone in the
balance of EDRFs such as nitric oxide and prostacyclin, and EDCFs such as
prostaglandin and thromboxane. Further studies are needed to grasp the
complexity of endothelial regulation in normal vascular tone and disease,
including the role of estrogen receptor-mediated endothelial signaling, which is
a focus of this thesis.
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1.6.3 Vascular Smooth Muscle Cells:
The vascular smooth muscle cells (VSMCs) comprise the medial layer of
arteries. VSMCs are arranged in a circumferential orientation around vessels.
This circumferential arrangement allows their contraction or relaxation to
modify the radius of a vessel, which inversely relates to flow resistance (i.e. a
contraction will decrease the radius and result in increased resistance to flow,
relaxation increases vessel radius and decreases resistance to flow). VSMCs
are connected to each other by gap junctions and are also connected to
underlying endothelial cells via myoendothelial gap junctions. The smooth
muscle also receives signals from circulating vasopeptides, peripheral
(sympathetic) nerves, vascular adipose and adventitial tissue to regulate
contractility.
There are three primary mechanisms that elicit vascular smooth muscle
contraction; electromechanical (membrane depolarization), cellular calcium
sensitization, and pharmacomechanical coupling (receptor-operated
mechanisms). Each of these distinct mechanisms, however, is intricately
linked in the mediation of contraction. Endothelial signals such as prostanoids
and nitric oxide travel to the adjacent VSMCs to effect vasorelaxation and/or
vasocontraction by a myriad of mechanisms, including myosin light chain
phosphatase (MLCP) stimulation or suppression, calcium mobilization, and
membrane depolarization (109, 110).
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The mechanisms of contraction in VSMCs depend on calcium activation of
the contractile apparatus. Increased levels of intracellular calcium activate
calmodulin (CaM), which phosphorylates myosin light chain kinase (MLCK),
which in turn phosphorylates myosin light chain (MLC). The phosphorylation of
MLC allows myosin to bind filamentous actin at the overlapping zone of the
contractile apparatus. Hydrolysis of ATP to ADP allows the myosin filament to
slide across the actin filaments, contracting the apparatus and effecting a
contraction of the smooth muscle cell. MLC can be deactivated by myosin light
chain phosphatase (MLCP), which is tightly controlled through multiple receptor
signaling pathways. Hence, the balance of MLCK and MLCP determines
calcium sensitivity of the contractile apparatus and thus plays a pivotal role in
mediating VSM tone. Intracellular calcium increases can occur in several
ways. The intracellular calcium concentration in a resting VSMC is about 100
nM, while the extracellular calcium concentration is about 1 mM. Hence there
is a natural concentration gradient for calcium to flow into the cell if appropriate
ion channels are open. Additionally, the intracellular membrane potential of a
resting VSMC is negative, which creates an electrical gradient for positively
charged calcium to flow into the cell if voltage-sensitive channels are opened
by receptor-operated stimuli or depolarization of the plasma membrane.
In the presence of a depolarizing stimulus for VSMC contraction (such as a
secondary kinase messenger, increased flow or high extracellular potassium),
activation of voltage or pressure-sensitive ion channels or inhibition of
potassium channels results in depolarization of the cell membrane, which
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activates voltage-gated calcium channels (VGCC). Influx of calcium through
these channels will activate ryanodine receptors at the sarcoplasmic reticulum
to activate calcium-induced calcium release (CICR), adding to the rise in
intracellular calcium to induce contraction.
1.6.4 Renin-angiotensin system (RAS) & reactive oxygen species (ROS)
in vascular smooth muscle:
An example involving pharmacomechanical-coupled VSMC contraction is
the vasopeptide angiotensin II (Ang II). Ang II is generated as part of a
complex and tightly regulated pathway referred to as the renin angiotensin
aldosterone system (RAAS). RAAS can be activated by a decrease in blood
pressure or an increase in sympathetic neural activity sensed by the kidney.
Initiation of the RAS response begins at the juxtaglomerular complex (JGC) at
the renal afferent tubule. Prepro-renin is secreted in response to the detection
of decreased flow in the afferent tubule. Prorenin is converted into the active
form renin in the macula densa cells of the JGC and released into the
circulation. Cleaved, activated renin is a catalytic protein that travels to the
liver where angiotensinogen is produced. Renin cleaves angiotensinogen into
the precursor peptide Angiotensin I within the liver. Circulating Ang I is cleaved
at the lungs by angiotensin converting enzyme II (ACE 2) into the vasoactive
peptide Ang II. This multi-step process ensures a tight regulation of Ang II
production. In some cases of hypertension there is an imbalance
(hyperactivation) of RAAS activity. Successful drugs used in the clinic to treat
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hypertension target RAAS components, such as inhibitors of renin and ACE2
activity as well as Ang II receptor (AT1R) blockers.
Ang II activation of AT1R receptors on VSMCs initiates a signaling
cascade that activates NADPH oxidase to increase production of superoxide
anion (O2˙). Superoxide is known as a “kindling radical” that can form additional
reactive oxygen species (ROS) in multiple cell types including VSMCs.
Superoxide can be converted into other forms of ROS, such as hydrogen
peroxide via the enzyme superoxide dismutase (SOD). ROS can mediate
VSMC contraction in multiple ways, including activation of IP3R for calcium
increase (111). Other mechanisms such as ROS-mediated activation of PKC
and RhoA kinase are areas of active research (112) (113) (114) (115).
The NADPH oxidase (NOX) protein family functions as a catalytic source
of superoxide anion. NOX expression is ubiquitous across cells types, with
certain tissues expressing greater amounts of specific isoforms, such as NOX2
in endothelial cells, NOX1 in vascular smooth muscle, NOX3 in phagocytic cell
types (such as macrophages) and NOX4 in adventitial fibroblasts (116). NOX5
is a specialized, calcium-dependent isoform expressed in multiple cell types
that is species-specific to humans or primates (i.e. not expressed in rodents).
The catalytic NOX complex is made up of several subunits and co factors. The
catalytic subunit of NOX exists as several isoforms, including NOX1, 2,3, 4 and
5. With respect to smooth muscle, the catalytic subunit NOX1 is located at the
plasma membrane and associated with the scaffolding protein p22phox. There
are also cytosolic NOX subunits including the low molecular weight GTPase
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Rac1 and several adaptor NOX subunits. These subunits can vary by cell type,
but in the vascular smooth muscle NOXO1 and NOXA1 reside with Rac1 in the
cytosol. Upon receptor-mediated stimulation, Rac1 ushers the translocation of
the cytosolic subunits to the plasma membrane for NOX assembly. When
activated, NOX forms the superoxide anion radical by transferring an electron
from its substrate NADPH through the FAD intermediate onto molecular
oxygen. Increased NOX activity has been shown to result in up-regulation of
NOX gene transcription, suggesting a positive feedback of NOX through ROSsensitive transcription factors (116).
It is known that a dysfunctional or hyperactivated RAAS can result in
increased ROS accumulation, contractile sensitization, proliferation and
hypertrophy of VSMCs, resulting in increased vascular resistance referred to
as hypertension (117-119). Chronic hypertension is one of the most prevalent
diseases in developed countries worldwide, and its progression is related to the
development of multiple CVD types such as heart failure or stroke. Its etiology
is complex and multifactorial including genetics, age, lifestyle and gender.
(120-122).
1.7 Estrogen, ER and GPER studies in endothelial cells:
It is well known that ERα activation contributes to multiple aspects of
endothelial function, including eNOS-mediated vasodilation (NO production),
vascular permeability, cell migration and upregulation of antioxidant-related
genes.
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In 2002, Chambliss et al. demonstrated a signaling mechanism for E2’s
protective effect in endothelial cells. They reported that E2 was able to
phosphorylate eNOS, the enzyme responsible for the production of the vital
vasodilator nitric oxide (NO), in a dose-dependent manner through a Gicoupled mechanism (98) (99). Evidence has shown that ERα associates with
eNOS in endothelial caveolae, where acylation of eNOS and palmitoylation of
ERα coordinate colocalization of the proteins at this specialized lipid raft. These
studies demonstrated that ERα activation could increase endothelial
bioavailability of NO through rapid activation of eNOS by ERα at the eNOS
activation sites Y81 and S1179. Additional studies in HUVECs show that ERα
may mediate complex protein-protein interactions of eNOS with co-factor
proteins such as Hsp90 (100). Membrane-associated ERα and its truncated
isoform ER46 (17) may activate several kinases upstream of eNOS including
ERK1/2, which activates phosphatases to dephosphorylate the inhibitory
residues threonine 495 and serine 615,as well as c-Src, which activates
tyrosine 81 (101) (102), and also PI3K/AKT, which phosphorylates ser1177
(101). Interestingly, the role of ER signaling in calcium mobilization and
subsequent calcium-mediated eNOS activation needs further investigation to
establish a mechanistic tie between these two events.
In terms of long-term regulation of eNOS or other antioxidant gene
expression, studies have shown that ERα activation with the isoflavone S(-)equol can activate the master transcription factor Nrf2, which is responsible for
the transcriptional regulation of multiple antioxidant enzymes by coordinating
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transcription complexes at antioxidant response elements (AREs) in the DNA
(103). ERα–mediated activation of Nrf2 depends on PI3K signaling (104). In
HUVECs, ERα activation has been linked to increased expression of hemeoxygenase, Nrf2, NOX2 ad VEGF (103). The upregulation of these genes by
ERα was dependent on PI3K intermediate signaling.
The activation of eNOS by E2 has not always been considered to be
beneficial. Studies by White et al. in 2005 and 2010 showed that E2-stimulated
eNOS activation in the presence of decoupled eNOS in endothelial cells
exacerbates oxidative stress by the scavenging of NO into the reactive oxygen
species (ROS) metabolite peroxynitrite (ONOO) (105) (106) . ROS
accumulation instigates endothelial dysfunction in two ways, first by reducing
NO bioavailability by oxidizing it into ONOO, and secondly by decoupling the
eNOS enzyme, switching its catalytic activity to produce superoxide. Hence,
stimulation of eNOS by E2 may actually promote endothelial dysfunction if the
endothelium is already in a ROS-enriched state, such as in atherosclerosis or
hypertension, although such mechanisms have yet to be demonstrated.
Using the GPER-specific agonist G-1, multiple groups have demonstrated
GPER-mediated activation of eNOS at the critical residue ser1177 in human,
rat and mouse endothelial cells (101, 107) (102). Since studies of GPER
signaling in multiple cell types have shown that GPER activates c-Src, ERK1/2
and PI3K/AKT signaling cascades, current research, including this thesis,
addresses the roles of c-Src, ERK1/2 and PI3K/AKT as secondary messengers
mediating GPER-induced NO production. The differential effects of SERMs
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and SERDs on GPER-mediated eNOS production are an intriguing area that
needs further study. In long-term genomic regulation of eNOS and/or
antioxidant-related enzymes, data have shown that addition of E2 to breast
cancer cell line MCF-7 increased expression of the antioxidant enzymes
glutathione peroxidase and Mn superoxide dismutase (Mn-SOD/SOD3) (108)
in an ERK1/2- and NFkB-dependent manner. The contribution of GPER to this
ERK-mediated expression may be implied in endothelial cells, but has not been
investigated. The contribution of GPER-mediated AKT activation is well known,
and the elucidation of a role (if any) for GPER in these signaling events has yet
to be directly demonstrated.
1.8 Estrogen, ER and GPER studies in vascular smooth muscle cells:
The majority of studies concerning E2 action in the vasculature focus on
endothelium-mediated NO production, but several studies do outline critical
activities of E2 in vascular smooth muscle cells (VSMCs). E2 has been
demonstrated to reduce proliferation in VSMCs in vascular ischemia models
using mouse carotid arteries (123). Additionally, E2 has been shown to
mediate decreases in VSMC proliferation, which can lead to hypertrophy of
arterial walls and increase vascular resistance, a critical component of
hypertension development. Inhibition of VSMC proliferation by E2 can also
combat the progression of atherosclerosis (124). E2 has also been shown has
to activate neuronal NOS and inducible NOS in VSMCs (125). While neuronal
NOS (nNOS) can be a contributor of NO in VSMC leading to vasodilation in
conditions of aging and hypertension (where a ROS-enriched cellular
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environment is present), excess NO can be scavenged by ROS into the
peroxynitrite radical (ONOO-), which in turn can exacerbate oxidative stress in
the VSMC (125). Studies by White et al. in 2005 and 2010 reported that E2
treatment of VSMCs in a state of uncoupled nNOS leads to increased
superoxide levels and increased coronary artery contraction (105). Thus, the
contributions of E2 in maintaining vascular health may be dependent on the
relative health of the VSM.
The role of GPER in mediating E2-induced acute VSMC signaling has
also been investigated. Studies by Lindsey et al. report that GPER can activate
smooth muscle adenylyl cyclase (AC) resulting in cAMP increases to induce
eNOS-independent vasorelaxation in isolated mesenteric arteries and smooth
muscle cells (106) (126). Yu et al. expanded on these studies using human
and porcine coronary artery smooth muscle cells to show that GPER-mediated
activation of AC leads to increased cAMP and activation of PKA to inhibit
RhoA/ROCK kinase activity, which promoted the activity of MCLP, resulting in
vasorelaxation (127). In terms of genomic effects of GPER in VSMCs, longterm activation of GPER by G-1 has been shown to down regulate AT1R
receptor (mRNA) expression (128). G-1 also inhibits VSMC proliferation in a
similar manner to that described previously for E2 (129). Additional studies of
GPER in the short and long-term regulation of vascular smooth muscle function
are needed to provide further insights into additional pathways, and the overall
balance of endothelial and VSMC signaling in arterial function.
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1.9 Estrogen, ER and GPER studies in isolated arteries:
In terms of acute vasoreactivity, the ability of E2 to induce NO-dependent
vasodilation in arteries of human, rat and mouse is well known (130) (131).
Kleinert et al. have also reported that E2 increased eNOS expression in an
ERα-dependent mechanism (132). Multiple studies indicate that both ERα and
GPER contribute to the actions of eNOS across different species and vascular
beds (54, 133). Our laboratory first reported the ability of the GPER-specific
agonist G-1 to directly stimulate vasorelaxation in an eNOS-dependent manner
in 2010 (54). Others and we have also shown that G-1 induces a modest,
eNOS-dependent vasorelaxation in thoracic aorta, mesenteric and carotid
arteries (126, 131, 134) of mice. Other reports have shown that GPERmediated (G-1) vasorelaxation in rat mesenteric arteries induced a similar
vasorelaxation response as E2, suggesting at least a collaborative role of both
receptors in mediating total vasorelaxation effects (130) (126). In rat cerebral
and pial arteries, the GPER agonist G-1 improved vascular function in an
eNOS-dependent manner, which increased protection in an ischemiareperfusion injury model of stroke (135). Furthermore, reduced vasorelaxation
to estradiol in arteries from aged rats (male and female) were found to
correlate with the downregulation of GPER expression with age (136).
Our laboratory has utilized the GPER KO mouse in characterizing the
actions of GPER in vasoreactivity. Our GPER KO mouse model shows similar
levels of eNOS expression compared to WT (137). Our colleagues in Zurich,
Switzerland previously reported that carotid arteries from GPER KO mice had
30

increased contraction to ET-1, and that these enhanced contractions were due
to elevated thromboxane production (137). These results suggested that
deletion of GPER increases endothelium-derived contraction responses to
thromboxane, suggesting GPER also promotes vasorelaxation by decreasing
EDCF activity. Finally, our laboratory has demonstrated that arteries isolated
from GPER KO mice have reduced basal NO levels in mice fed an
atherosclerotic diet, but NO levels in healthy GPER KO mice are not different
from WT (138).
Studies by Lindsey et al. demonstrated that a small portion of GPERmediated vasorelaxation occurs in an eNOS-independent mechanism by
activation of smooth muscle adenylyl cyclase activation and cAMP increase in
mesenteric smooth muscle cells. They confirmed their observations from
cultured primary cell systems in arterial function by showing vasorelaxation of
mesenteric arteries through GPER activation through an adenylyl cyclase and
cAMP mechanism (126) in endothelium denuded human coronary artery
vasocontraction (127). Interestingly, in human coronary arteries Yu et al.
demonstrated a larger G-1-mediated vasorelaxation response in endotheliumdisrupted human coronary arteries. Finally, studies from 2010 demonstrated a
vasocontraction response to E2 in coronary arteries with pharmacologically
uncoupled NOS, which serves as a pharmacologic model of vascular disease
(105). Taken together, the effects of GPER in vasorelaxation may vary
substantially between vessel bed and disease state.

31

1.10 Estrogen, ER and GPER studies in whole animal and humans:
In contrast to the multiple mechanistic reports of E2 and GPER in vascular
cell types and whole vessels, studies of E2 replacement in both rodents and
humans have yielded complex results. Chambliss et al. report that non-nuclear
pools of ERα are responsible for mediating protective cardiovascular effects
(such as reduced hypertrophy and maintenance of NO bioavailability) in the
absence of breast epithelial cell or uterine proliferation (139). It has also been
demonstrated that acute E2 infusion directly at the tissue of rat hearts reduced
coronary vascular resistance and increased coronary blood flow (140). In
terms of chronic E2 infusion, there are mixed results of vascular reactivity and
protection. Studies of E2 replacement in male or ovarectomized female ApoEdeficient mice have shown positive effects, such as protection against
atherosclerotic plaque development and reduced oxidative stress in the
vascular wall in a high-cholesterol diet (72, 141). Our laboratory has also
demonstrated that infusion of GPER-specific agonist G-1 provides the same
level of protection against atherosclerotic plaque formation and reduces
inflammation in arteries of mice on an atherogenic diet (107). Chronic infusion
of G-1 has also been shown to decrease blood pressure in ovarectomized
females, but not male rats, and to reduce cardiac remodeling in rat models of
hypertension (128, 142).
Human studies of E2 replacement provide less clear results of E2 in vivo.
While acute administration of E2 in patients improved vasodilator responses
and reduced cardiac ischemia (143), chronic infusion (directly into circulation)
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of E2 in post-menopausal hormone replacement therapy (HRT) trials have
yielded mixed results. Such results were dependent on the source and dose of
exogenous estrogen, the age of women treated (relating to the length of time
they had been post-menopausal) and their state of preexisting CVD (144). An
early study of estrogen replacement, the Nurses' Health Study in the 1970s,
indicated E2 replacement reduced CVD risk by 35-50% vs. placebo (145).
However, later studies such as the Women’s Health Initiative (WHI) in the
1990s and the Heart and Estrogen Replacement Study (HERS) in 2002
showed no vascular protection and even reported aberrant cardiovascular
dysfunction (143, 146, 147). The WHI examined the effects of exogenous E2
replacement in menopausal women using conjugated equine estrogens
(CEEs). Although the WHI was originally designed to examine the effects of
estrogen supplementation from CEE to treat post-menopausal symptoms, the
study was suspended due to an increased incidence of stroke and myocardial
infarcts (148).
Despite these trials, it has been considered that the activation of specific
post- estrogen receptor signaling pathways is key to maintaining vascular
protection while circumventing deleterious side effects (143). Pharmacologic
targeting of GPER-specific pathways using the GPER-specific agonist G-1 has
shown promising results in animal models for the activation of favorable
estrogenic pathways in vascular tissues. Chronic infusion of G-1 in rats
resulted in decreased blood pressure (128), but neither the ERα KO nor GPER
KO mouse models are intrinsically hypertensive (149) (150). In some cases,
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E2 or G-1 protected from certain forms of hypertensive challenge in rodents
(130), but have failed to protect against increased blood pressure in other
rodent models (151). Both E2 and G1 infusion have been shown to protect
against atherosclerosis in mice (107, 141). However, in some cases, G-1
infusion in rats protected females, but not males (151) from salt- sensitive
hypertension.
1.11 Rationale, Hypothesis and Specific Aims:
The mixed results of the literature demonstrate the complex biology of
estrogen and its receptors, which suggest that there are additional pathways
not yet identified that could be contributing to the often unclear effects of
estrogen replacement and vascular health. There are suggested vascular
benefits of estrogen, but the role of GPER in mediating these benefits is still
unclear.
The goal of this dissertation project was to address gaps of knowledge in
GPER signaling in endothelial and vascular smooth muscle, and to implement
these findings into a functional context of vessel reactivity and whole animal
models. These cell types engage in dynamic cross talk signaling for
maintenance of stable peripheral resistance and proper blood pressure control.
Maintenance of blood pressure is vital for perfusion of peripheral tissues and
organ function. The direct signaling pathways of GPER, as well as the role of
GPER in SERM/SERD-mediated effects in endothelial and smooth muscle
cells and whole vessel function remain unclear. Elucidation of the specific
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signaling pathways of GPER will aim to resolve conflicting results in animal and
clinical studies concerning estrogen in vascular function, and is significant for
progression in the fields of gender medicine and vascular biology. To address
these gaps in knowledge, two specific aims were proposed for examining the
signaling pathway(s) of GPER in endothelium and vascular smooth muscle
(Fig 1.8):
Specific Aim 1: Determine the signaling pathway and contribution of GPER
to estrogen-mediated eNOS activation and NO production. We hypothesize
that GPER regulates a portion of the estrogen-stimulated production of NO
through stimulation of eNOS in an AKT/PI3K pathway to activate eNOS residue
ser1177, and that genomic deletion or pharmacologic inhibition of GPER
reduces the vasorelaxation response to estrogen.
Subaim 1.1: Determine the signaling pathway and contribution of GPER
to the activation of eNOS in an ERα-independent manner in endothelial cells.
Subaim 1.2: Assess the effects of GPER deletion on vasorelaxation to E2
using GPER KO mice.
Subaim 1.3: Determine the role of GPER in mediating the effects of
SERMS in endothelial NO production and vasorelaxation to SERMs tamoxifen
and raloxifene and the SERD ICI 182,780.
Specific Aim 2: Determine and characterize the effects of GPER
signaling in Ang II-mediated contraction of vascular smooth muscle. Based on
preliminary data showing a role for GPER in endothelial NO generation, we
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hypothesize that GPER KO arteries will have an increased vasocontraction
response to Ang II due to reduced NO levels, which may result in a
hypertensive phenotype in rodents due to a loss of NO-dependent
vasodilation.
Subaim 2.1: Identify and characterize a role of GPER in Ang II-mediated
smooth muscle contraction and vasotone by utilizing the GPER KO mouse
arteries and primary VSMCs.
Subaim 2.2: Elucidate the acute and/or genomic cellular mechanism(s) of
GPER in Ang II contraction in genomic deletion (GPR KO) and pharmacologic
conditions (short or long-term employment of G36 to inhibit GPER).
Subaim 2.3: Examine the effects of GPER deletion (KO) and
pharmacologic inhibition (G36) in a mouse model of RAS-mediated (Ang IIinduced) hypertension.
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Fig 1.1

Fig 1.1 Estrogen synthesis is a multi-step process: Cholesterol is converted to pregenenolone,
DHEA , and finally into the androgen androstenedione in the thecal cells of the ovary.
Androstenedione can be converted into testosterone by the enzyme 3βHSD. Both androstenedione
and testosterone are converted into estrogens by the P450 enzyme aromatase. Androstenedione
is first converted to estrone by aromatase and then into estradiol by the enzyme 17β HSD.
Testosterone can be directly converted to estradiol by aromatase. Aromatase is expressed at the
granulosa cells (but not thecal cells) in ovary and at some peripheral tissues (endothelial cells
adipose and liver) for estrogen synthesis. Modified from Ray & Gupta, Drugs Fut 2006, 31(1): 65
ISSN
0377-8282
Copyright
2006
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0377-8282
DOI:
10.1358/dof.2006.031.01.959122
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Fig 1.2

Estrone

17β-Estradiol

Estriol
Fig 1.2 There are three variants of endogenous estrogens: Estrogens are named relative
to the number of hydroxyl groups they have. Estradiol is the predominantly active form in
premenopausal women, while estrone is the predominant form in post-menopausal women.
Modified from Ahokas, R, McKinney, E, Glob. libr. women's med., (ISSN: 1756-2228) 2008; DOI
10.3843/GLOWM.10101
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Fig 1.3
ERα structure (595 aa, 66 Kda):
COOH-- AF-1 domain

0

C domain

D (hinge) domain

263

184

--NH2

E/AF 2 domain

302

595

ERβ structure (530 aa, 62 Kda):
COOH-- AF-1 domain

C domain

149

D (hinge) domain

214

124

E/AF 2 domain --NH2

530

Co-factor binding
DNA binding
Hinge domain
Ligand (E2) and cofactor binding
Fig 1.3 classical estrogen receptor and structure : The classical estrogen receptors alpha
and beta share an 96% homology at the C and D domain and approximately 30% and 60%
homology at the AF-1 and AF-2 domains, respectively (ER β relative to ER α). At the
C terminus there is an AF-1 binding domain for co-factors. The C domain is responsible for DNA
binding. The D domain is a “hinge” domain where the receptor changes conformation upon
ligand binding at the E/AF-2 domain at the amino terminus. Additional co-factors can bind the
AF-2 domain. Despite receptor homology, ERβ is largely considered to have opposing effects to
ERα in most tissues.
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Fig 1.4 A

Fig 1.4 Estrogen receptors signal by genomic and rapid pathways: A) In genomic or
“classical” signaling, activated ERs form homo or hetero dimers, and act as transcription factors
for gene regulation by binding at estrogen response elements (EREs) at promoter regions. There
are three forms of classic signaling, direct signaling is where ERs bind directly at the DNA,
tethered or indirect signaling where dimerized ERs form a complex with multiple transcription
factors and/or co-factors which then bind the DNA as a complex, and ligand independent signaling,
where secondary kinases such as ERK 1/ 2 activate ERs by phosphorylation of the receptors to
mediate downstream transcription factors. Modified from N. Heldring et.al. Physiological Reviews
Published 1 July 2007 Vol. 87 no. 3, 905-931 DOI: 10.1152/physrev.00026.2006
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Fig 1.5

Fig 1.5 signaling pathways of the G protein-coupled estrogen receptor: Following GPER
binding to ligand E2, c src is phosphorylatedin through the alpha protein Gs. SRC activate matrix
metalloprpteases (MMPs) which cleave heparin bound EGF into its active form to bind EGFR.
Activated EGFR can also activate src, ERK1/2 and PI3K/AKT kinase signaling. GPER can also
activate adenylyl cyclase via Gs coupled alpha protein. AC can activate PKA signaling and RhoA
kinase for multiple downstream kinase effects. GPER activation of A Gq alpha protein can
activate Phospholipase C (PLC) which will cleave PIP2 into DAG and IP3. IP3 activate IP3
receptors to increase intracellular calcium. DAG can activate PKC which is also an important
secondary messenger of multiple targets. Modified from Gigoux & Fourmey, Front. Endocrinol.,
29 April 2013 | doi: 10.3389/fendo.2013.00050
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Fig 1.6

Fig 1.6 GPER specific targeting
compounds: G-1, the GPER specific
agonist has a ethanone moiety to
increase steric hindrance to prevent
ERα/β binding. The GPER-specific
antagonist G36 replaces the ethanone
moiety with a methyl group to prevent
binding with ERα/β. Modified from
Dennis & Prossnitz et.al. 2003.

17β-ethinyl estradiol
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Fig 1.7

ICI 180,76
(Fluvestrant)

Fig 1.7 SERMs and SERDs have differential tissue
dependent effects: Raloxifene and Tamoxifene are
SERMs which alter ER signaling in a tissue specific
manner. ICI182,76 (fluvestrant) is a SERD that targets
ERs for proteosomal degradation. Adapted from
Howell et al Best Pract. Res Clin Cndocrinol Metab
2004 Mar;18(1):47-66cam
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Fig 1.8
E2, G-1

GPER
Endothelial
eNOS
AT1R

NO

NOX
Smooth
muscle

GPER
relaxation

O2contraction

Fig 1.8 Investigative schematic of GPER in endothelial and smooth muscle
signaling in vascular regulation: This thesis aims to investigate mechanism by which
GPER signaling may activate endothelia NOS (eNOS) with by rapid signaling and/or
genomic regulation to promote NO production.
At the smooth muscle, we aim to
elucidate the role of GPER in mediating Ang II vasoconstriction and NOX induced
superoxide production in both rapid signaling and genomic functions.
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CHAPTER 2
G PROTEIN-COUPLED ESTROGEN RECEPTOR CONTRIBUTES TO
ESTROGEN-MEDIATED ACTIVATION OF ENDOTHELIAL NITRIC OXIDE
SYNTHASE AND VASORELAXATION
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2.1 ABSTRACT
Although the ability of 17β-ethinyl estradiol (E2) to induce rapid activation of
endothelial nitric oxide synthase (eNOS) was reported over a decade ago, the
pathways and relative contributions of ERα and the more recently described G
protein-coupled estrogen receptor (GPER) are unresolved. Given that rapid
signaling of GPER acts through cross-activation of EGFR and PI3K/AKT, and
that AKT is responsible for eNOS activation at ser1179, we hypothesized that
GPER activates eNOS at ser1179 in an EGFR and AKT-dependent mechanism.
We report that GPER-specific agonist G-1 induced phosphorylation of eNOS at
the activating residue ser1179 in endothelial cells with a maximal activation at
100 nM. We found that pharmacologic inhibition of GPER with G36 reduced E2mediated NO production by ~60%. Inhibition of nitric oxide synthase enzymes
with LNAME blocked G-1-mediated NO production, indicating NO production by
GPER is an eNOS-specific event. Inhibition of EGFR (AG1478) and PI3K/AKT
(LY291004) reduced NO production to GPER agonist G-1 by 85% and 76%,
respectively. Inhibition of the kinase intermediate c-Src (PP2) inhibited NO
production to G-1 by ~70%, and ERK1/2 inhibition (PD98059) blunted NO
production to G-1 by ~80%, suggesting that GPER activates eNOS through
multiple pathways and regulatory residues. Genomic deletion of GPER in mice
(GPER KO) resulted in a 45% reduction in vasorelaxation to E2 in thoracic aorta.
Finally, we report that inhibition of GPER in endothelial cells reduces NO
production to the selective estrogen receptor modifier (SERM) compound
tamoxifen (4-OHT) and to the selective estrogen receptor downregulator (SERD)
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ICI 182,780. As the effects of clinical estrogen replacement therapy (ERT) have
had unclear results for protecting vascular health in post-menopausal women,
the implication of GPER agonism (G-1) as a possible therapeutic for increased
NO production is a promising alternative.
2.2 INTRODUCTION:
Once thought of as a simple barrier layer, the vascular endothelium is now
known as a diverse regulatory tissue of vascular reactivity, blood pressure,
leukocyte extravasation, and serves as a source of growth, clotting, and other
paracrine factors (152, 153). In the 1980s, Nobel laureate studies by Furchgott
et al. identified the endothelium as the source of a vascular relaxation factor,
which they termed endothelial-derived relaxation factor (EDRF) (154). These
studies instigated a landslide of research that went on to characterize the
signaling cascades and functions of endothelium in secreting EDRF, which was
later identified as nitric oxide (NO) (155), in mediating arterial relaxation (156).
The enzymatic source of NO for vasodilation is endothelial nitric oxide
synthase (eNOS), a multi-unit heterologous enzyme. Although several isoforms
of nitric oxide synthase (NOS) have been identified such as inducible NOS
(iNOS) and neuronal NOS (nNOS), eNOS is the predominantly expressed
isoform in endothelial cells and the largest contributor of NO in healthy vascular
function. NO formation is catalyzed by eNOS in two steps: first by transferring an
electron from NADPH substrate through FAD+ onto molecular oxygen at the
eNOS heme-domain, and second by cleaving nitrogen from the amine group of
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an arginine substrate. The short half-life of NO (20-30 sec) necessitates rapid
diffusion from the endothelium to the smooth muscle through the myoendotheilal
gap junctions (157). Several groups have characterized eNOS co-localization
with cholesterol-rich caveolae domains of the plasma membrane, and have
described a post-translational acylation of eNOS that modifies the enzyme for
anchoring to the caveolae scaffolding protein caveolin-1 (cav-1) (158, 159) (160).
Additionally, post-transcriptional palmitoylation of ERα promotes trafficking to
caveolae and association with cav-1/eNOS complexes (28). Physiologic
mediators of eNOS activation include shear stress and pressure- sensitive
receptor tyrosine kinases, which induce downstream AKT activation and
phosphorylation of eNOS at ser1179 (161) (162). The neurotransmitter
acetylcholine (Ach) can act on muscarinic type 3 (M3) G protein-coupled
receptors on endothelial cells in experimental settings, which will increase
intracellular calcium for calcium-dependent eNOS activation as well as PI3K
/AKT activation and phosphorylation of eNOS at ser1179.
Clinical studies show that the incidence of CVD in pre-menopausal women
is lower compared to men until the onset of menopause, when the rate of CVD in
women rapidly equalizes to that of men (163-165). These observations suggest
the loss of ovarian hormones coincided with a loss of protection against CVD in
women, implicating a protective role of E2 in CV health.
Investigations of the receptors and pathways mediating E2 signaling in the
vasculature have focused on ERα and the more recently described G proteincoupled estrogen receptor (GPER, formerly GPR30). Once thought to only exert
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chronic, genomic effects through nuclear-localized ERα and β, studies
demonstrating rapid signaling responses to E2 through ERα and GPER have
been characterized in vascular cells (63, 166). Multiple studies have shown that
activation of ERs and/or GPER induces vasorelaxation in an eNOS-dependent
manner (54, 98, 130, 136). However, the contributive roles of ERα and GPER
and their mechanisms in eNOS activation by E2 and other ER-targeting
compounds (SERMs and SERDs) remain unresolved. We hypothesized that
GPER co-mediates acute activation of eNOS by E2 and contributes to total NO
production to estrogen with ERα. We sought to extrapolate the signal
transduction pathway for GPER-mediated eNOS activation, and to determine the
contribution of GPER to E2-mediated vasorelaxation by the endothelium. To
answer these investigative points, we utilized molecular approaches to determine
eNOS phosphorylation and NO production, and conducted vascular reactivity
studies in the GPER KO mouse.
2.3 METHODS:
2.3.1 TIVE cell culture: Telomerase-immortalized human umbilical vein
endothelial cells (TIVEs) were a generous gift from the Renne laboratory at the
University of Florida (Gainesville, FL), and their derivation has been described
previously (167). TIVEs were cultured in M199 basal media supplemented with
20% FBS, 1 μg/mL penicillin, streptomycin and gentamycin antibiotics and 100
μg/mL bovine neural derived endothelial growth factor (Sigma). TIVEs were
cultured up to passage 12, and Western blotting for GPER expression for
endothelial and fibroblast markers was performed every 4 passages.
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2.3.2 Western Blotting: TIVE cells were grown to 80-90% confluence in 6 cm
dishes, experimentally treated, and lysed on ice with 80 μL of NP-40 lysis buffer
supplemented with 1% SDS, 5 μM sodium orthovanadate and 5 μM NaF to
preserve phosphorylated proteins. Samples were centrifuged at 10,000 xg and
supernatant was collected and stored at -80°C. For each sample, 20 μg of total
protein was resolved by 10% SDS PAGE and blotted to PVDF membrane. Blots
were blocked for 1 hour at room temperature in TBS-T 0.01% supplemented with
3% newborn calf serum and incubated overnight at 4°C with the following
antibodies: 1:500 phospho- eNOS (mouse IgG S1179, BD Science cat #612392),
1:10,000 β- actin (mouse IgG Millipore MAB1501), and 1:10,000 GPER targeting
second extracellular loop (clone #9368, rabbit IgG).
2.3.3 Nitric Oxide detection: Nitrate byproduct was assessed as indirect
detection of total nitric oxide (NO) using the AbCam Nitric Oxide detection Kit
(ab#65328). Following treatment, in HEPES buffered physiologic saline solution
(in mmol/L: 134 NaCl, 6 KCl, 1 MgCl2 , 1 CaCl2, 10 glucose 10 HEPES; pH 7.4),
TIVEs were lysed at room temperature in sample buffer, and either stored
overnight at -80°C or immediately loaded to a 96-well plate and treated with
nitrate reductase and nitrate reductase substrate. Samples were incubated at
room temp for 90 min to convert nitrates. Griess reagents were used to develop
azo purple to measure nitrate levels. Photometric detection of azo purple
absorbance at 540 nm was read on a Syngergy H1 plate reader at room
temperature. Three readings per plate were taken. Background signal was
subtracted and net azo signal was normalized to total protein (determined by
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Coomassie blue readings at 533 nm) for each replicate. Samples were done in
triplicate and experiments were repeated at least 3-5 times.
2.3.4 DMT isometric tension studies: Thoracic aorta was excised from male
mice of BL6 WT or GPER KO littermates aged 3-5 months (25-30 g). Aorta was
cleaned of fat in ice-cold PSS (in mmol/L: 129.8 NaCl, 5.4 KCl, 0.43 NaH2PO4,
19 NaHCO3, 1.6 CaCl2, 5.5 glucose; pH 7.4), cut into 3 mm rings, and mounted
onto pins of a DMT myography chamber, and allowed to recover at 37°C for 30
min. Isometric tension was applied to a resting tension of 1900 mg and two
successive contractions to 60 mM KCl were conducted. Viability was assessed
as PE contraction (1 μM 5 min) response to 70% of the KCl max reading, and at
least at 70% relaxation of the PE response by 1 μM acetylchoine (5 min). Rings
were pre-contracted with PGF2α to 30-40% of the KCl max value, and dilation
response to 3μM of E2, G-1 or ethanol vehicle were recorded for 60 min.
Meclofenamate (1 μM 30min) was added 30 min prior to pre-contraction with
PGF2α and subsequent estrogen dilation to E2 or G-1.
2.3.5 Statistical Analysis: N= 3-10 separate experiments for all studies.
Unpaired T test was used to determine differences in mean between treatment
groups, and error bars represent SEM. A p-value less than 0.05 was considered
experimentally significant.
2.3.6 Animals care and use: All animals were housed according to IACUC
protocols and animal procedures were approved by the University of New Mexico
care and compliance of animal welfare guidelines. Mice were given ad libitum
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access to water and standard chow. Animals were anesthetized with 1 mg/kg
sodium pentobarbital, and response to pain was assessed by toe web pinch prior
to opening the peritoneal cavity. The diaphragm was exposed and cut to ensure
animal death.
2.4 RESULTS:
2.4.1 GPER activation contributes to estrogen mediated NO production by
activation of eNOS at ser1179. GPER expression in TIVEs was confirmed by
fluorescence microscopy (Fig 2.1 A). We first examined the effects of GPERspecific agonist G-1 on activation of eNOS by determining the phosphorylation
status of the critical activation residue ser1179 in human TIVE cells. We
observed a G-1-mediated, dose-dependent increase in phosphorylation of eNOS
at ser1179 with a significant activation at 100 nM compared to vehicle (Fig 2.1
B)(53 +/-7 vs. 19+/-4 n=4, p=0.035). We next sought to confirm that activation of
eNOS by G-1 increased NO production using colorimetric detection of nitrates.
Detection of NO demonstrated that Ach (536 +/-4.7), E2 (425+/- 4) and G-1 (308
+/-4.3) increased NO production in TIVEs (vs. veh 94.0 +/-0.5, p= 0.006, n=4-6),
and that non-selective ER activation (E2) induces greater NO production than
GPER activation alone (Fig 2.2). Our results here confirm the observations of
others (126) (131) that GPER can mediate eNOS activation and NO production
in endothelial cells independently of ERα. The augmentation of NO production to
E2 likely arises from the collaborative signaling of both ERα and GPER in
mediating non-selective ER-induced eNOS activation.
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We next sought to determine to contribution of GPER activity in E2mediated NO generation in endothelial cells. Using GPER-specific antagonist
G36 (100 nM 30min). We found that acute pharmacologic inhibition of GPER
(G36) reduced NO production to E2 by ~60% (407 +/-3.0 and 235 +/- 2, p=0.009,
n=6), but did not reduce NO production to acetylcholine (Fig 2.3) (543+/-12 vs.
533+/-9, p=0.838, n=5-8). These data suggest GPER partially contributes to E2mediated NO production in endothelial cells, but does not contribute to E2independent mechanisms of eNOS activation, such as Ach-induced eNOS
activation.
2.4.2 GPER induces NO production in endothelial cells through multiple
pathways. We next sought to determine the secondary signaling kinases
involved in GPER-mediated eNOS activation. To determine the signaling
pathway of GPER in eNOS activity, inhibitors targeting multiple constituents
previously reported in the GPER pathway (35, 168) (33, 169) were used to
assess the pathway of GPER- mediated NO production in endothelial cells. One
well-known mechanism of GPER signaling is cross-activation of the epidermal
growth factor receptor (EGFR). GPER activates G proteins to activate c-Src
kinase, which activates MMPs to induce the shedding of EGFR ligand heparinbound EGF. EGFR activation mediates a substantial number of downstream
secondary messengers such as PI3K/AKT, which lies directly upstream of eNOS
phosphorylation at ser1177, and ERK1/2, has been shown to phosphorylate both
the inhibitory residues threonine 495 and serine 116, as well as the crucial
activating residue ser1179 of eNOS. Both GPER and EGFR activate c-Src
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kinase, which can directly activate residue tyrosine 81 on eNOS (170). Inhibition
of EGFR with AG1478 reduced NO production to G-1 by 85% (210.4 +/-1.4 vs.
42.7 +/-2.8), and reduced NO production to E2 by 86% (211.7 +/-9.4 vs. 51.6 +/1.1), indicating that both GPER and classic ERs signal through EGFR for eNOS
activation (Fig 2.4 A).
Next, the PI3K/AKT inhibitor LY294002 (1 μM) was used to inhibit NO
production to E2 or G-1 (100 nM) in endothelial cells. PI3K/AKT inhibition
significantly abrogated NO production to both G-1 and E2 by ~76% in each case
(E2 422.3 +/-2.5 vs. 196.3 +/-1.6) (G-1 337.3 +/- 5.5 vs. 185.7 +/-2.2) (Fig 2.4 B),
suggesting that non-selective ER (E2) and GPER-specific activation of eNOS
occur in a PI3K/AKT-dependent manner. Both non-selective ER-mediated (E2)
and GPER-specific (G-1) NO production were eNOS-dependent, as
demonstrated by a reduction of 80% (140 +/-5.68 vs. 54.99+/-5.31) and 85%
(180.5 +/-52.5 vs. 56.14 +/-4.65) of NO production to G-1 and E2 in TIVE cells
pretreated with the NOS inhibitor LNAME (1 μM for 30min) (Fig 2.5).
The involvement of ERK1/2 and c-Src signaling in GPER-mediated eNOS
activation was determined using ERK inhibitor PD98059 (3 μM) and c-Src
inhibitor PP2 (3 μM) prior to G-1 or E2 stimulation of eNOS in TIVE cells.
Inhibition of c-Src (PP2) reduced NO production to G-1 by nearly 70%
(140+/=5.56 vs. 53.5+/-7.39 p=0.08) (Fig 2.5), and reduced NO production to E2
by ~70% (180+/-52.5 vs. 65.01 +/- 4.82) suggesting an additional signaling axis
of GPER-mediated eNOS activation through c-Src, likely through activation
EGFR for phosphorylation of ser1179 as well as c-Src phosphorylation of residue
55

tyrosine 81. Inhibition of ERK1/2 with PD98059 reduced NO production to G-1
by ~60% (140+/- 5.56 vs. 59.43 +/-11.04 p=0.002). Inhibition of ERK1/2 also
reduced NO production to E2 by ~60% (180 +/- 52.5 vs. 71+/-13.3 p=0.08). As
ERK1/2 has been debated as both an activating kinase for ser1179, and also as
a mediator of phosphorylation of the inhibitory residue Threonine 495 on eNOS.
Given our data here, we suspect that ERK1/2 signaling contributes to activation
of eNOS mediated by GPER and ERα through phosphorylation of activating
residues rather than through inhibition of eNOS at Thr495, or at least the
activation of eNOS overrides any inhibitory effects of ERK1/2 through ERmediated signaling.
2.4.3 GPER inhibition reduces NO production induced by selective
estrogen receptors modulators (SERMs). Selective estrogen receptor
modifiers or downregulators (SERMs/SERDs) are used in the clinic for a variety
of treatments, both pro-estrogenic and anti-estrogenic, depending on the tissue
and cell type (171). SERMs impart pharmacologic effects by activation or
inhibition of classic ERs, however SERM classification is specifically defined by
their effects on classic ERs, regardless of their modifications to GPER signaling.
For example, the SERD ICI 182,780 and SERM tamoxifen (4-OHT) have been
demonstrated to act as antagonists towards ERα but conversely act as GPER
agonists (56). Since some SERMs and SERDs have been previously reported to
have effects on improved endothelial function (56, 171), and yet are shown to
have inhibitory effects on ERα in multiple cell types (56), we hypothesized that
the SERMs tamoxifen and raloxifene and the SERD ICI 182,780 would induce
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NO production through agonism of GPER. TIVEs were pretreated with vehicle
(0.01% DMSO) or 100 nM G36 for 30- 45 minutes prior to administration of
tamoxifen activated metabolite 4-hydroxy tamoxifen (4-OHT) (1 μM), raloxifene (1
μM), or ICI 182,780 (1 μM) for 10 min prior to cell lysis and NO colorimetric
detection. Acute pharmacologic inhibition of GPER (G36) reduced NO
production to 4-OHT by ~53% (121 +/-12 vs. 57.65+/-.0625, p=.039). GPER
inhibition also reduced NO production to ICI 182,780 by ~27% (106+/-9.77 vs.
77.6+/-6.7 p=0.04). Inhibition of GPER produced a trend in decreased NO
production to raloxifene, but was not statistically significant (p=0.086) (Fig 2.6).
These data indicate that GPER plays a minor role in mediating NO production to
SERMs, or that SERMs may have ER-independent effects in mediating
endothelial health and function.
2.4.4 GPER genomic deletion decreases vasorelaxation to E2 but not
SERMs and does not alter murine systolic blood pressure. Since GPER
inhibition reduced NO production in TIVEs, we next tested the physiologic output
of GPER-mediated eNOS-dependent vasorelaxation in mouse thoracic aorta
response to E2 or G-1 in WT BL-6 or GPER knockout (GPER KO) mice. Thoracic
aorta from GPER KO mice had a ~45% reduction in relaxation (-35% +/- 7.42%)
to general estradiol mediated dilation (E2 3 μM) compared to E2 dilation in WT
aorta (-63%+/- 6.43%) (Fig 2.7). The vasorelaxation response of KO aorta to Ach
(1 μM) did not differ from WT dilation to Ach (-93% +/- 3.52 vs. 95%+/- 5.68),
corroborating earlier results from NO production in TIVE cells that inhibition of
GPER had no significant effect on Ach induced NO production.
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Interestingly, there was no statistical difference between vasorelaxation
responses to E2 (non-selective ER activation) or GPER-specific (G-1) in mouse
thoracic aorta (Fig 2.7). Our data here are in agreement with previous reports by
Lindsay et al and Yu et al (172) (127) and also agree with our data from NO
colorimetric detection in TIVEs that G-1 and E2-mediated NO production did not
significantly differ in most aspects, or differed only by a marginal amount (Fig
2.2). These results suggest that GPER is sufficient for mediating total ERinduced vasorelaxation responses, but that ERα may not be. It is possible that
non-selective ER activation by E2 may be involved in counteractive pathways
against eNOS activation (such as ERK2-mediated phosphorylation of inhibitory
residue threonine 495 on eNOS) as data from the TIVEs suggest. Given that
COX activity was inhibited with meclofenamate prior to observing vasorelaxation
responses to G-1 or E2, it is unlikely that E2-induced EDCF production would
counteract an E2-induced vasorelaxation response obesrved in our myography
experiments.
Vasorelaxation to the SERD ICI 182,780, and the SERM (activated)
metabolite 4-hydroxy tamoxifen (4-OHT) were tested in WT thoracic aorta
pretreated with vehicle (.01% DMSO) or G36 (1 μM) to assess the role of GPER
in mediating the vasorelaxation effects of these compounds (Fig 2.8). Data on
SERM myography indicated that GPER inhibition did not significantly blunt
vasorelaxation to ICI 182,780 or 4-OHT. These results suggest that the SERM
and SERD compounds have alternative signaling pathways, including possibly
ER-independent pathways.
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Since GPER is shown to contribute to estrogen-mediated NO production
and vasorelaxation, we sought to assess if GPER genomic deletion had effects
on global blood pressure in male or female mice compared to WT littermates. We
employed conscious tailcuff readings of systolic pressure, whereby mice were
trained to sit quietly under light restraint for 90 seconds to obtain 6 readings of
systolic pressure daily for 7 to 10 days (see section 2.3 for detailed methods).
Using conscious tailcuff blood pressure measurements, we found that systolic
blood pressure in the GPER KO mice was no different from WT in young (3
months) and aged (16 month) male or female mice (Fig 2.9 A). Heart rate from
these animals were no different between WT and GPER KO mice, suggesting
that there was not a compensatory change in heart rate to regulate systolic blood
pressure (Fig 2.9 B).
2.5 SUMMARY & DISCUSSION:
In summary, we show that GPER contributes to E2-mediated acute eNOS
activation by showing that G-1 induced eNOS phosphorylation at ser1179,
promoted NO production, and by showing that inhibition of GPER (G36) results in
decreased NO production to E2. NO detection revealed that non-selective ER
activation and GPER-specific activation induces eNOS-dependent NO production
through multiple pathways including EGFR, PI3K/AKT, c-Src and ERK1/2. We
also demonstrated a 55% reduction of the relaxation response to E2 in thoracic
aorta of GPER KO mice. We demonstrated a contributive role of GPER in SERM
mediated NO production through eNOS activation in endothelial cells. Finally, we
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showed that systolic blood pressure was no different between WT and GPER KO
mice.
Previous studies have clearly implicated a role for estrogen in
cardiovascular health (71, 130). These vasoactive effects appear to be mediated
primarily through an eNOS-dependent mechanism, which can be activated both
by non-selective ER agonism and GPER-specific activation. However, recent
studies have presented an additional GPER mechanism for vasorelaxation at the
smooth muscle level though GPER-mediated activation of smooth muscle Gs
and adenylyl cyclase to increase cAMP and activate PKA and RhoA kinase for
increase MLCP activity and reduced contraction in VSMCs by calcium
desensitization (126, 127). To date, studies have not elucidated the exact
contribution of GPER activation in endothelial NO production, nor the exact
signaling pathway of GPER in estrogen-mediated eNOS activation and how it
compares to signaling pathway of ERα. The data presented here is significant
and progressive in several aspects in that it reveals the pathway of GPER
signaling in eNOS activation, and demonstrated for the first time that the E2mediated relaxation response is reduced with genomic deletion of GPER in
GPER KO mice.
We build upon the current body of knowledge using molecular approaches
and knockout animal studies to resolve the differences between GPER and ERα
in eNOS activation in TIVEs. We showed that GPER-mediated eNOS activation
likely occurs through the regulation of multiple regulatory residues due to its
activation of multiple eNOS-interacting kinases, such as PI3K/AKT, c-Src and
60

ERK1/2, which lends to the complex effects of estrogen in endothelial function.
Additionally, we demonstrate that the complex effects of SERMs and SERDs in
mediating endothelial function is only partially dependent on GPER signaling,
which implicates that SERMs or SERDs may have additional effects outside of
modifying ER signaling, or that they have differential effects in the endothelium
(activating rather than antagonizing).
While the predominant body of work studying ER-mediated vasorelaxation
derives from investigations of eNOS-dependent mechanisms, several other
sources of endothelial derived relaxation factors (EDRF) exist. Prostacyclin
(PGI2) is a vasodilator compound derived from metabolism of arachidonic acid
intermediates by endothelial cyclooxygenase (COX) enzymes. Inhibition of COX
1 and 2 in multiple vessel types, including the thoracic aorta rings used in these
studies did not diminish vasorelaxation to G-1 nor E2, indicating that COXderived EDRFs are likely not involved in estrogen-mediated vasorelaxation.
Additionally, previous studies by our laboratory investigating increased
vasocontractility in obesity models of GPER KO and high fat diet mice showed
that GPER deletion had no effect on COX-mediated vasocontraction increases
from thromboxane sensitization in adipocytes (173), which further indicate GPER
is not involved in COX-mediated signaling for vessel tone or relaxation.
Additionally, multiple independent reports show that inhibition of NOS activity
using LNAME in endothelial cells abrogates NO production to E2 and G-1 (126)
(172) (174) (166). These observations demonstrate that E2-mediated
vasorelaxation is likely an eNOS-dependent mechanism.
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We must also consider endothelial derived hyperpolarizing factor (EDHF),
which is another mechanism of endothelial regulation of tone and vasorelaxation.
Some studies show that EHDFs may persist for adjacent hyperpolarization of
adjacent VSMC when both eNOS and COX are inhibited, at least in some
vascular beds (175) (176) (177) either by possibly acting through endothelial
small and intermediate conductance (SK and IK) channel activation, or by
diffusible factors from endothelial cells that activate smooth muscle ion channels.
It has also been hypothesized that NO can act directly as a hyperpolarizing
agent. Additionally, GPER-specific agonist G-1 has been shown to induce
hyperpolarization in some vascular beds (possibly in a secondary manner
through the actions of NO) (176, 178). Our myography studies did not address
mechanisms of ERα or GPER in EDHF responses, and as such we cannot
exclude the possibility of a partial contribution of this signaling mechanism in E2
and GPER-mediated vasorelaxation.
Our systolic blood pressure data showed no difference in SBP between
GPER KO and WT mice regardless of sex or age. These data, along with our
myography studies, agree with previously published observations that GPER
agonism does not intrinsically reduce blood pressure in mice (172) (179).
However, estrogen receptors are hypothesized to mediate observed gender
differences in blood pressure and susceptibility to hypertension (130, 134).
Other laboratories have documented a hypotensive phenotype in different strains
of GPER KO mice (174) and others have demonstrated that G-1 infusion lowers
blood pressure in rats (128). Also, recent data has demonstrated that a single
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nucleotide polymorphism resulting in a hypofunctional GPER variant occurs in
approximately 30% of the female population and is associated with a subtle
increase in resting blood pressure (180). Given these reports, the role of GPER
in maintaining blood pressure is unclear. In mouse models, there may be
compensatory effects in the genomic deletion of GPER, such as increased ERα
signaling to substantiate E2-mediated NO production, or decreased cardiac
output to maintain mean arterial blood pressure in response to increased
peripheral resistance in our GPER KO animals. It is also possible that we were
unable to observe subtle differences in systolic blood pressure due to our method
of measurement with tailcuff. Although conscious tailcuff measurement of SBP
has been implemented in many instances to show differences in experimental
models where shifts in BP can be more dramatic (such an Ang II infusion or high
salt diet vs. control normotensive), this method may not be sensitive enough to
measure subtle differences in SBP in healthy mice. To this effect, a
compensatory change in heart rate may have occurred in these animals, but
again our data from the CODA 6 system may not have been sensitive enough to
detect such changes.
This study also presents characterization of an endothelial cell line that
has not been previously used to study endothelial pathways of estrogen, the
Telomerase Immortalized human umbilical Vein Endothelial (TIVE) cell line (167).
Our data establish the molecular and functional identity of TIVEs as a useful
reagent in conducting endothelial studies for estrogen mechanisms. Myography
data in this study also corroborated our results established in the TIVEs, further
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implicating their utility in conducting molecular studies on estrogen signaling in
endothelial biology. Stable expression of GPER, ERα and endothelial markers
and low expression of mesenchymal markers throughout passaging implicate
TIVEs as a novel reagent to study endothelial signaling with the convenience of
cell line stability derived from a well-known tool for endothelial studies, the
HUVEC.
It must be noted that cultured endothelial systems cannot accurately
represent a response from an endothelium in vivo. For example, a vital
component of endothelial function is the response to shear stress along the
luminal surface, which is a classic stimulus for shear induced, NO mediated
vasodilation. While our cell culture system cannot take into account the signaling
differences that may arise from a system incorporating shear stress stimulation of
NO production, we can establish that E2 stimulation of endothelial cells can lead
to an increase in NO production, and also result in NO-mediated vasorelaxation
at the tissue level, which was independent of shear stress. We hypothesize that a
shear stress exposed endothelium may have a stronger response to E2
stimulation because of increased basal NO due to shear stress exposure, which
is further augmented with receptor-mediated activation. We additionally
recognize here that myography of aortic rings also lacks a flow-response design
that more accurately mimics in vivo endothelial responsive conditions for
vasodilation. Nevertheless, the acute reactivity of a vasorelaxation response (in
the absence of intraluminal pressure, but holding at optimal resting tension) to
agonist-induced (G-1 and E2) was readily measured in our system, which
64

suggests that ER and GPER stimulation of NO and vasorelaxation can occur
independently of shear-induced eNOS activation.
Taken together, this study utilized unique tools such as TIVEs and the
GPER KO mouse to establish the detailed GPER signaling axis for eNOS
activation, and resolved the contribution of GPER to E2-mediated vasorelaxation
in thoracic aorta and blood pressure maintenance in the GPER KO mouse.
Importantly, the GPER-specific agonist G-1 and GPER-specific antagonist G36
are useful reagents in that present research suggests these compounds lack the
deleterious side effects seen with generic estrogen replacement or with other
SERMs known to have tissue-specific effects or complications (181). Studies of
E2 replacement in mouse studies as well as in hormone replacement therapy
(HRT) clinic have presented mixed results of E2 in mediating CVD risk reduction
(120, 143, 182). Here, the resolution of the GPER signaling axis and its
contribution to E2-mediated dilation further enrich the resourcefulness of G-1 and
G36 as compounds that could have broad clinical implications in reducing CVD
risk in post-menopausal women by promoting eNOS activity, increasing NO
bioavailability and maintaining endothelial function. Given that there are GPER
specific agonists (G-1) and antagonists (G36) that avoid deleterious
complications of estrogen replacement (143), it is plausible that GPER-specific
modulation could aid in promoting or maintaining cardiovascular function in postmenopausal women, given the lack of reproductive side effects GPER-specific
compounds have such as uterine weight gain seen with estrogen replacement or
supplementation in mice (51) (183) (E2) or ERα-antagonizing SERMs or SERDs
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such as tamoxifen or ICI 182,780. Additionally, the efficacy of GPER-mediated
NO in the endothelium can also deliver vasoprotective effects from
atherosclerosis and inflammation. To this effect we published such results
demonstrating GPER agonist G-1 indeed reduces atherosclerotic plaque
development and inflammation in mice fed an atherogenic diet (107). We may
conclude that a mechanistic implication of this protective effect stems from
GPER-mediated NO production by the data given in this thesis. We conclude
that GPER may moderate multiple cardiovascular benefits such as
vasorelaxation by promoting eNOS activation and NO production, and that this
mechanism is essential for mediating the benefits of estrogen signaling in
cardiovascular health.
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Fig.2 GPER activation stimulates eNOS phosphorylation at ser1179: A)
GPER expression in TIVEs was confirmed with fluorescence microscopy. B)
TIVE cells were treated with increasing doses of GPER-specific agonist G1 for 20 min, lysed and blotted for phosphorylation of eNOS critical
activation residue ser1177. C) Densitometry of 2B shows that GPER
activation increased eNOS phosphorylation in a dose-dependent manner.
*p=0.03 vs. veh

67

Fig 2.2

Fig 2.2 GPER activation induces nitric oxide production: TIVE cells were
treated with 100 nM of estrogen (E2), GPER agonist G-1, acetylcholine (Ach) or
0.01% DMSO vehicle control (veh) for 10 min and were lysed and subjected to
Griess reagent detection of nitrate byproducts as an estimate of NO production.
Both non-specific ER activation (E2) and GPER-specific activation (G-1) resulted
in NO production. Estrogen mediated NO production was not as robust as Ach.
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Fig 2.5
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Fig 2.5 E2-mediated NO production requires c-Src and ERK1/2: Endothelial cells
were pretreated with 1 μM of NOS inhibitor LNAME (A) c-Src inhibitor PP2 (B), or
ERK1/2 inhibitor PD98059 (C). Inhibition of eNOS blocked NO production to estrogen
and GPER specific activation. Inhibition of c-Src and ERK1/2 kinases also prevented
NO production to E2 and GPER-specific agonist G-1. These data indicate that multiple
pathways of activation are required to elicit the E2 and GPER induced production of NO.
*P<0.05 vs. E2, #P<0.05 vs. G-1 or E2 without inhibitor
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Fig 2.6

Fig 2.6 GPER inhibition reduced NO production to selective estrogen receptor
modifiers and down regulators: Endothelial cells were pretreated with GPER-specific
antagonist G36 (1 μM) or 0.01% DMSO vehicle for 30-40 min., and treated with SERMs 4
hydroxy-tamoxifen (4OHT) or raloxifene, or the SERD ICI182,76 for 15 min. Inhibition
partially blocked NO production to 4OHT and raloxifene, as well as blocked NO production
to the ICI182,76.
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Fig 2.7
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Fig 2.7 Genomic deletion of GPER results in reduced vasorelaxation to E2 in
thoracic aorta: Thoracic aorta harvested from GPER KO mice or WT BL-6
littermates were subjected to isometric force myography to measure vasorelaxation
to E2 (3 μM )or to acetylcholine (1 μM) .Aortas were precontracted with PGF2α and
then treated with a single dose of Ach or E2. Vasorelaxation is expressed as a
percent reduction from the PGF2α precontraction value. Compared to WT aorta,
GPER KO aorta displayed a 45% reduced vasorelaxation to estrogen (E2). There
was no observed difference in vasorelaxation between GPER KO and WT aorta to
acetylcholine. N=6-8 animals per treatment, * P< 0.05 vs. WT E2
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α

Fig 2.8

Fig 2.8 GPER inhibition does not reduce vasorelaxation to tamoxifen or ICI 180,76:
thoracic aorta form WT mice were pretreated with GPER-specific antagonist G36 (1 μM 30
min) prior to vasorelaxation with the active metabolite of tamoxifen (4-OHT) or ICI180,760.
GPER inhibition did not significantly reduce vasorelaxation to either compound.
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Fig 2.9

Figure 2.9 GPER KO animals do not exhibit increased systolic blood pressure: Mice
that were wildtype (WT) or GPER null (GPER KO) were subjected to conscious talicuff
measurement of systolic blood pressure (SBP) at 3,6,12,and 18 months of age. The graph
above depicts SBP at 18 months of age. There was no detectable difference in SBP between
GPER KO and WT littermates at any age point. N=4-5 per group.
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Fig 2.10
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Fig 2.10 Summary of chapter 2 findings: Using a human endothelial cell line, it was
determined that GPER activation induces NO production by eNOS through several signaling
pathways including EGFR and PI3K/AKT which are upstream of ser1171, and c-Src activation
which is upstream of Y87, and ERK1/2 which is upstream of thr495. GPER specific agonist
G36 also reduced NO production to the SERMs tamoxifen and raloxifene, as well as reduced
NO production to the SERD ICI182,76.
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CHAPTER 3
GPER REGULATES NADPH OXIDASE EXPRESSION AND SUBSEQUENT
SUPEROXIDE PRODUCTION TO ANGIOTENSIN II IN VASCULAR SMOOTH
MUSCLE
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3.1 ABSTRACT:
Reactive oxygen species (ROS) are an essential mediator of vascular smooth
muscle cell (VSMC) signaling and contractility. A catalytic source of ROS is the family
of NADPH oxidase (NOX) proteins. As such, pharmacologic regulation of NOX
activation and/or expression could serve as a potential therapeutic to reduce oxidative
stress, which is a common component to vascular disease such as hypertension.
Myography studies imparted a novel observation that the arteries from mice expressing
global knockout for the g protein-coupled estrogen receptor (GPER KO) have reduced
contraction to vasopeptide Ang II compared to wild type (WT) arteries. The reduction
seen in KO arteries was mimicked in WT by pharmacologic inhibition of NOX using the
gp91ds-tat peptide. Lucigenin detection showed that VSMCs from GPER KO animals
had a remarkable loss of superoxide production to Ang II and NADPH compared to WT
and human VSMCs, as well as a reduced calcium response, coinciding with reduced
arterial contraction seen in our GPER KO vessels. Chronic, but not acute inhibition of
GPER reduced superoxide production in WT mouse and human aortic SMCs,
suggesting a genomic mechanism of regulation of GPER over NOX1. Indeed we found
a ~50% reduction in NOX1 expression in GPER KO SMC, as well as a 50% reduction in
NOX1 expression in human aortic SMCs treated with G36 (p= .0227). To assess the
physiologic efficacy of our findings, we tested GPER inhibition or deletion abrogated a
hypertensive response to Ang II peptide infusion. GPER KO and G36-pretreated WT
animals resisted hypertension onset, and their vessels had reduced superoxide levels
compared to hypertensive WT animals. These data implicate that GPER partly mediates
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expression of NOX1 in VSMCs, and that inhibition of GPER can subsequently reduce
ROS levels to mitigate Ang II-induced hypertension by decreasing NOX1 expression.
3.2 INTRODUCTION:
Reactive oxygen species (ROS) are a vital molecular component of cellular
signaling and physiologic function, and has long been implicated in normal vascular
function. Disruption of the ROS balance has been demonstrated as a causative factor
in atherosclerosis, hypertension, and stroke (184, 185). Although multiple forms of ROS
exist, the superoxide anion radical (O.) is a special type of ROS, generated in part by a
family of enzymes, NADPH oxidases (NOX), expressed in most cells. In the
vasculature, NOX1 is commonly expressed in smooth muscle, while NOX2 is expressed
in endothelial cells and NOX2 and NOX4 in adventitial fibroblasts (185, 186). Typically,
NOX catalytic enzymes function by transferring an electron from the substrate NADPH
through FAD+ onto molecular oxygen to generate the superoxide anion radical,
although the isoform NOX4 exclusively generates hydrogen peroxide (H2O2) (185, 186).
Superoxide has been shown to oxidize cysteine residues of ROS-sensitive transcription
factors and other downstream signaling targets such as VEGF, hypoxia inducible factor
(HIF), and protein kinase C (PKC) (187, 188). Additionally, superoxide and other types
of ROS (such as H2O2) can activate voltage gated L-type calcium channels (L-VGCC),
and IP3 receptors (IP3R), which drive cytosolic calcium increase (189). PKC activation
and intracellular calcium increase are implicated in myosin light chain kinase (MLCK)
activation and smooth muscle contraction. Ang II, a vasoconstrictor peptide binds to
AT1R receptors at the smooth muscle, which activates a signaling cascades such as
rac1 to promote assembly and activation downstream NOX to produce ROS in vascular
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smooth muscle cells, resulting in arterial contraction (190-192). The superoxide anion
can also be rapidly reduced to H2O2 by the enzyme superoxide dismutase (SOD), or
oxidize the nitric oxide radical (NO) into the ROS peroxynitrate (ONOO-), and hence
also serves as a “kindling” radical for downstream ROS generation and activation of
multiple ROS-sensitive targets (184).
In 2005 and 2010, Experiments by White and colleagues described a novel effect
of estrogen (E2) inducing contraction in porcine coronary arteries when nitric oxide
synthase (NOS) enzymes were uncoupled with L-NNA, resulting in increased ROS
production and ROS-mediated contraction (105) (106). However, the receptor(s)
involved and subsequent signaling mechanism(s) were not fully established, including
sources of ROS separate from pharmacologic disruption of NOS. Importantly, these
studies failed to address signaling differences between estrogen receptors such as
alpha, beta or GPER when conducting mechanistic studies on the contractile effects of
estrogen in NOS-uncoupled aortas and VSMCs (106). Interestingly, the Women’s
Health Initiative (WHI) clinical study in 1991 concluded that post-menopausal women
suffered a 30% increase in CVD from synthetic estrogen replacement, suggesting that
estrogen may play a role in post-menopausal CVD (193). Taken together, these
separate reports may implicate a mechanistic effect of E2 to induce ROS production in
arterial contraction and vascular dysfunction.
The deregulation of NOXs in hypertension has been described in several animal
models (185, 194-197). In 2005, Griendling et al. reported that NOX1 overexpression in
transgenic rats exacerbates an Ang II-model of hypertension. Conversely, inhibition of
NOX using siRNA or gp91ds-tat (NOX peptide inhibitor) abrogated Ang II-mediated
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hypertension (198, 199). Several mechanisms of NOX activation have been addressed
in the literature, such as a feedback loop of Ang II receptor AT1R to cross activate both
epidermal growth factor receptor (EGFR) and NOX1 (200, 201), as well as NOX1generated superoxide cross-activation of EGFR via c-Src oxidation (202) , and EGFR
activation of ERK1/2 to activate transcription factors MEF2B and JunB for increasing
NOX1 transcription (203).
Our laboratory has reported that GPER can cross-activate EGFR (40) in several
cell types by activating c-Src to activate matrix metalloproteases (MMPs) which cleave
and activate heparin-binding EGF (HB-EGF), a ligand for EGFR. This link may be
important in SMC for GPER in mediating superoxide production via EGFR crosstalk with
NOX in the mechanisms listed above. GPER functions have already been partially
characterized in endothelial function and CVD (130, 135, 204); however, more
investigation in vascular smooth muscle is needed to fully understand GPER function in
the vasculature.
Whereas previous reports implicated an ability of E2 to promote oxidative
damage in lieu of uncoupled NOS or diseased arteries, our studies here expand upon
this observation to establish new insights regarding E2 in cardiovascular health through
the contribution of GPER signaling to the oxidative damage connected to E2
replacement in clinical studies. While we originally hypothesized that GPER KO
animals would have an increased Ang II contraction due to reduced eNOS activity from
lack of GPER, we report here a novel observation that GPER KO animals have reduced
Ang II contraction. This reduced contraction arises from diminished NOX expression
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and results in decreased ROS production to the vasopeptide Ang II in VSMCs, as well
as in a rodent model of ROS-mediated hypertension.
3.3 METHODS:
3.3.1 Aortic SMC harvest and culture: Ex vivo harvest of fresh murine smooth
muscle cells from aorta of GPER KO and WT age-matched littermates were used to
study the signaling mechanisms of superoxide production. Mice were euthanized with
sodium pentobarbital (0.1mg/kg ip). Aortas were dissected from mice and cleaned of fat
in ice-cold sterile HPSS (HEPES-buffered saline solution, pH 7.4) supplemented with
penicillin, streptomycin and gentamycin. Collagenase I digest (1mg/mL) was performed
at 37°C for 20 min to loosen the adventitia. Adventitia was then peeled off the vessel,
the vessel was cut open lengthwise, and endothelium rubbed off with a sterile toothpick.
The tissue was washed twice with sterile HPSS and allowed to rest for 2 hours in
DMEM with 10% FBS in a humidified 37°C incubator. Aortas were incubated in digest
buffer containing elastase I and collagenase I at 37°C for 20 min to disperse SMCs.
Digested aortas were titurated with a sterile glass pipette, digested another 25 min and
titurated again to disperse the smooth muscle cells. Cells were collected and seeded in
2 mL of DMEM with 10% FBS and antibiotics. Primary AoSMC’s were split 1:2 to in T25 flasks coated with 0.01% Poly-L lysine and cultured to passage 4 for experiments.
QPCR and for α-actin, GPER, and Vimentin (a fibroblast marker) were used to ascertain
the purity of primary VSMC culture.
3.3.2 Lucigenin detection of superoxide production to assess the role of GPER:
To determine if there are differences in superoxide generation between direct chronic
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inhibition of GPER and the global GPER KO mouse-derived SMCs, we examined the
role of the GPER in Ang II and NADPH-induced superoxide production in WT and
GPER KO primary aortic smooth muscle cells. Lucigenin is a cell-permeable dye that is
specifically reduced by superoxide to emit luminescence at 550 nM, resulting in indirect
detection of superoxide in live cells in real time. At 90% confluence cells in p.2 to p.4
were pretreated with GPER antagonist G36 for short term (30 min) and long term (3
days) prior to harvesting for lucigenin analysis. These conditions simulated acute
inhibition and genomic loss of GPER, respectively. Cells were trypsinized, washed in
warm HPSS, counted twice, and resuspended in 200 μL HPSS prior to lucigenin
detection. A final working concentration of 5 μM lucigenin was prepared by adding 50
μL of 25 μM lucigenin per well of a white opaque 96-well plate. After 5 min of dark
adaptation at 37°C in a Synergy H1 plate reader, 200 μL of cell suspension is added to
the wells, resulting in a final concentration of 5 μM lucigenin. Total luminescence
readings were recorded at 37°C every 20 sec for 10 min to obtain a baseline. After
taking a 10 min baseline, 100 nM Ang II (final concentration) was added per well and
luminescence reads every 20 sec for 20 min. Following Ang II readings, 100 μM
NADPH was added and luminescence recorded under the same conditions. In some
cases, NOX-specific inhibitor gp91ds-tat (3 μM) will be used to pretreat WT or KO cells
for 30 min prior to lucigenin analysis. Luminescence will be calculated as 5-minute
interval averages over 20 min of treatment, minus the background reading average at
10 min, and normalized to cell number.
3.3.3 DHE analysis of superoxide levels in live primary VSMCs: DHE was
employed as an additional detection method of indirect superoxide detection to confirm
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superoxide dynamics between WT and GPER KO SMC and frozen aorta. The dye
dihydroethidium, or DHE, is specifically oxidized by superoxide into hydroethidium,
which emits red fluorescence. At passage 2 or 3, cells were seeded into an 8-well
coverslip chamber coated with 0.01% poly-L lysine. Cells were washed with warm PBS
and treated with 5 μM DHE in HPSS for 20 min at 37°C on a rocking platform in the
dark. In some cases, cells will be treated with 100 nM Ang II at 10 min into the 20 min
DHE incubation. Alternatively, some cells will also be pretreated with 3 μM gp91ds-tat
for 30 min prior to DHE or DHE/Ang II incubation. DHE was gently aspirated off and
cells were carefully washed twice with warm PBS and viewed within 5-10 min on an
epifluorescence scope (Zeiss Axiovert 200M) with a rhodamine filter at 10x.
3.3.4 DHE fluorescence on aortic rings: Following two weeks of Ang II osmotic pump
treatment (Alzet Corp. 0.7 mg/kg/day) with placebo or G36 pellet (0.7 mg/kg/day),
animals were euthanized (1mg/kg sodium pentobarbital, ip) and the thoracic aorta was
excised, cleaned of surrounding fat in ice cold HEPES-PSS (pH 7.4), and embedded in
OCT (TissueTek, VWR) over methylbutane prechilled with liquid nitrogen, then stored at
-80°C for future use. Tissue samples were cut into 10 μM sections on a cryostat at 30°C, and slides were stored at -80°C for future use. Upon removal from -80°C slides
were immediately traced with a PAP pen and immediately incubated with 5μM DHE in
HEPES-PSS (pH 7.4) or vehicle (0.01% DMSO in HEPES-PSS) for 15 min at room
temperature in the dark. Slides were carefully washed twice and gently wet- mounted
with HEPES-PSS, and immediately imaged using epifluorescence at 10X on a Zeiss
Axiovert microscope with a rhodamine filter. At least 3-4 aortic slices per animal were
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used, and at least 3 images of each slice (i.e, 9-12 images per animal) were used to
assess an average representative image.
3.3.5 RNA isolation from cells and tissues: At 80% to 90% confluence in p.2 to 3,
primary AoSMCs were scrapped in a T-25 flask with 500 μL of TriZol reagent (Sigma)
on ice, and stored at -80°C for future use. RNA was extracted with chloroform (200μL
per 1 mL trizol used) and precipitated with 70% ethanol. Samples were subjected to
DNAse I digest, and cleaned on RNEasy columns according to manufactures
instructions (Qiagen). RNA was eluted into 30 μL RNAse free water, quantified with a
NanoDrop and stored at -80°C. Approximately 300 ng of RNA was used as input for
reverse transcription synthesis of cDNA.
3.3.6 QPCR to assess GPER genomic effects on NOX expression: To investigate a
genomic contribution of GPER to NOX-related gene expression, we resolved
differences in NOX transcript expression between WT, KO and GPER-inhibited cells.
Untreated WT, GPER KO SMCs and, WT SMC treated with 100 nM GPER specific
antagonist G36 or 0.01% DMSO for 3 days were used. Media was replaced with fresh
G36 or vehicle every 24 hours. RNA was extracted as described above and quantified
by averaging 3 readings on a NanoDrop spectrometer. Approximately 300 ng of RNA
per sample was reverse-transcribed (Applied Biosystems RT kit), and diluted at 1:9 in
RNAse free ultra-pure water. Subsequent QPCR performed with SYBR green
detection, and relative quantification determined using GAPDH as a housekeeping
gene. Mouse primers were used for the following targets: NOX1, NOX 2, NOX 4, p22,
p47phox, p67phox/NOXA1, AT1R, AT2R, NOXO1, and Rac1. Raw cT values were
normalized to GAPDH expression, and comparison of relative transcript expression to
85

untreated WT SMC as a positive control was calculated and graphed as arbitrary units
or percent expression of WT, as indicated.
3.3.7 Western blotting to determine NOX1 levels in GPER KO and WT SMC:
Primary cells derived from WT (BL-6) or GPER KO aorta were lysed in sub-confluent
(70-80%) T25 flasks at p.3 on ice using NP-40 lysis buffer supplemented with 1 μg/mL
protease inhibitor (sigma), 10% SDS, 0.5% NaF and 0.5% sodium orthovanadate by
volume. Lysates were centrifuged at 13,000xg for 10 min at 4°C and soluble
supernatant was aliquoted and stored at -80°C. For sample preparation for Western
Blot, 20 μg of lysates (determined by Coomassie colorimetric assay) were
supplemented with 6X Lamelli buffer and heated to 95°C for ten minutes to denature
proteins. In the case of GPER blotting, 30 μg of lysate was used.
Lysates were resolved on a 10% SDS PAGE and blotted onto PVDF membrane
for 90 min at 75 volts on ice. Blots were blocked in 3% newborn calf serum (NCS) TBST (0.01%Tween-20) at room temperature for one hour. Blots were then carefully cut
and blotted for NOX1 (10 μg/mL, polyclonal rabbit IgG, Sigma #4200097), beta actin
(millipore, mouse IgG 1:10,000), alpha actin (Abcam mouse IgG 1:1,000) or GPER
antibody targeting the second extracellular loop (clone 9368, rabbit IgG 1:5,000) in 3%
NCS TBS-T overnight at 4°C with gentle rocking. Blots were washed three times for 5
min each with TBS-T at room temperature, incubated with appropriate HRP-conjugated
secondary antibody at 1:5,000 TBS-T for one hour, and washed three times in PBS-T.
Blots were developed with Super Signal West Pico Chemiluminescent substrate
(ThermoSci cat#34087) and imaged on X-ray film. Quantification of band intensity of
NOX1 was ratiometrically determined by taking the densitometry ratio of target band to
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corresponding beta actin band in Image-J. When needed, blots were stripped using
Restore stripping buffer (Thermoscientific cat#21059) for 20-30 min at room
temperature and washed three times in TBS-T. Blot were briefly imaged to ensure no
bands remained, and re-blocked for 1 h in 3% NCS TBT-T before reprobing with
primary antibodies overnight at 4°C.
3.3.8 Immunofluorescence of NOX1 expression in VSMC: At passage 2, WT or
GPER KO SMCs were seeded into a 24-well plate on coverslips with Poly-L lysine. In
some cases WT cells will be pretreated 3 μM gp91ds-tat for 30 min as a negative
control. Cells will be treated with 100 μM NADPH for 2-20 or 30 min. Cells will be
washed twice with PBS, fixed in 4% PFA on ice for 15 min, and blocked in phosphate
buffered saline with 0.01% Tween-20 (PBS-T) for 1 hour at 25°C. Cells will be
incubated in primary antibody against NOX1 (rabbit IgG Sigma SAB4200097) at a
dilution of 0.5 μg/mL in 3% BSA PBS-T overnight at 4°C in a humidified chamber. The
next morning, cells were washed three times for 5 minutes in PBS-T, and incubated with
FITC conjugated anti-rabbit secondary antibody at 1:500 at 25°C for 1 hour in the dark.
Cells were washed three times in PBS-T, washed briefly with nano-pure H2O, and
mounted with vectasheild mounting medium and type 00 coverslips. Slides were
imaged with a Leica confocal microscope using 480 nm excitation.
3.3.9 Human Aortic smooth muscle cell culture: Primary Aortic human smooth
muscle cells (18 yo male no history of CVD cat#CC2571 cryovial of 500,000) were
purchased and shipped from Lonza (Bethesda MD). Cells were seeded at 3,350
cells/cm2 using the SmGm2 bullet kit of basal growth media with supplements and
antibiotics (Lonza cat#CC3182). Cell were passaged at 70-80% confluence and split at
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1:3. To ensure quiescence prior to experiments, cells were incubated in serum free
media overnight prior to lucigenin experiments or collection of lysate or RNA.
3.3.10 Chronic and acute pharmacologic GPER inhibition G36 in huSMC:
A final concentration of 100 nM G36 was prepared in 4 mL full serum SmGm2 media
and human VSMCs cultured in T-25 flasks (to 70% confluence) were washed twice with
1X PBS and replaced with G36 infused media. Fresh G36 was thawed and used to
prepare a 100 nM concentration in media to replace old G36 media every 24 hours.
Prior to experiments, cells were washed and replaced with 100 nM G36 in serum free
media overnight. Some flasks were treated with media containing 0.01% DMSO as a
vehicle control. For acute G36 doses, cells were washed with warm PBS and treated
with 100 nM G36 in serum free DMEM 30 min prior to experiments.
3.3.11 siRNA (siGPER) transfection in human SMC: Small inhibiting RNA targeting
GPER mRNA for degradation was used as an additional method to confirm the effects
of chronic inhibition of GPER on NOX1 expression in GPER KO and human aortic
VMSCs. For each transfection, 200 picomoles of siRNA was combined with 5 μL of
lipofectamine 2000 reagent at ambient temperature for 20 min in 1 mL total volume of
low serum DMEM, (0.1% FBS) and then added to a T-25 flask containing 2 mL for a
final volume of 3 mL of low serum DMEM overnight. This recipe was multiplied for as
many T-25 flasks as needed. The next day, flasks were washed and replaced with full
media (10% FBS). Human smooth muscle cells were used from passages 3-5 at 80%
confluence. After 72 hours post transfection, cells were either subjected to lucigenin
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analysis, or harvested for protein using 400 μL of NP40 base buffer. GPER, NOX1 and
NOX 2 expression inhibition were assessed by Western blot.
3.3.12 NOX1 adenoviral transduction of KO VSMC: Adenovrial constructs of
GFPlaboratoryeled NOX1 and control GFP adenoviral vector were graciously provided
by Dr. Bernard Lesengue at Vanderbilt University. Cells were transduced with a viral
titer of 300 vpm in 3 mL total volume of low serum (0.1% FBS) DMEM basal media
overnight. The next day virus media was washed off and replaced with full DMEM (10%
FBS) media. A positive infection was considered to be at least 70% expression at 72
hours, as confirmed by GFP positive cells versus total cells in bright field microscopy
images taken every 24 hours.
3.3.13 Animal surgery for Ang II osmotic pump and subcutaneous pellets:

Ang II

is the principal effector of the renin-angiotensin system and plays a major role in the
initiation and progression of hypertension. To test if the absence of GPER abrogates
NOX activity, which is a primary mediator of the Ang II effects in the vascular wall, we
tested whether GPER deficiency or inhibition prevents hypertensive response to Ang II
by reducing the superoxide response. Ang II was delivered by mini-osmotic pumps
(Alzet model 2002, Durect Corp), a safe, well-documented/published device for
controlled release of research agents. The mini-pump was implanted in the
intrascapular region to permit subcutaneous delivery of Ang II (0.7 mg/kg/d) or vehicle
(PBS) for 14 days in adult male WT and GPER KO mice. Some WT animals will be
simultaneously treated with the GPER-selective antagonist G36 or agonist G-1. A 21day time-release pellet of GPER-specific antagonist will be inserted 3 days prior to Ang
II pump insertion to deliver G36 at 0.7mg/kg/day throughout the study.
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3.3.14 Conscious tailcuff systolic blood pressure measurement: To assess a role
for GPER in maintaining superoxide and NO in hypertension, it is vital to examine
readouts of vascular pathology, such as increased systolic blood pressure (SBP), in an
animal model to test the involvement of GPER in mediating the development of
hypertension. Tail cuff measurement of BP is beneficial in that heart rate and pressure
are not compromised by anesthesia, and readings can be taken over several time
points during the hypertensive development. Conscious tail cuff measurement of blood
pressure will be assessed using the CODA 6 tail cuff machine (Kent Scientific), a wellpublished method of BP measurement (205-207). Mice were trained for 3 days prior to
beginning the study. Three sessions of five readings per animal (15 sec per reading)
were taken daily to calculate average SBP per animal per group preceding to (for
baseline) and throughout the two week study. Animals were given one day to recover
from each surgery before resuming readings. Daily averages from each animal were
compiled to calculate an average daily BP for each treatment group of 4-5 animals.
Group averages were graphed at 3-day intervals along the x-axis.
3.4 RESULTS:
Given that majority of previous studies demonstrated a role of GPER in eNOS
mediated vasodilation and NO generation (126) (208) (107) (54, 71), we had
hypothesized that genomic deletion of GPER (GPER KO) would result in an increased
contraction response to Ang II due to reduced NO levels. The experiments
characterizing contraction to Ang II in WT and GPER aorta (figure 3.1 of this
dissertation) were performed by post-doctoral fellow Dr. Matthias M. Meyer, MD. In
stark contrast, myography of thoracic aorta from GPER KO animals displayed a 58%
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reduction in contraction to Ang II (Fig 3.1 A). These data suggested that GPER KO
animals had a reduced or inactive component of Ang II-mediated contraction. To
assess the integrity of the Ang II signaling pathway in smooth muscle contraction in
GPER KO vessels, several inhibitors relating to the Ang II pathway were used in WT
arteries in an effort to mimic the reduced contraction seen in GPER KO arteries.
Interestingly, the peptide inhibitor gp91dstat, an inhibitor of the NADPH Oxidase (NOX)
catalytic enzyme of the reactive oxygen species superoxide, reduced WT contraction to
Ang II to similar levels seen in GPER KO arteries (Fig 3.1 B). Furthermore, gp91ds-tat
inhibition of NOX had no additive effect on contractile reduction in the GPER KO
arteries, implicating a role for GPER in mediating NOX-generated superoxide in Ang IImediated contraction.
3.4.1 GPER deletion reduces superoxide production to Ang II and NADPH in
primary aortic VSMCs. To further characterize superoxide formation in WT and GPER
KO vascular smooth muscle cells (VSMCs), we derived primary aortic VSMCs from our
GPER KO mice and their WT littermates. Confocal microscopy and western blot
confirmed the absence of GPER expression in our KO VSMCs (Fig 3.2 A,B), and
demonstrated that GPER localized to cytosolic membranes and neither the plasma
membrane nor nucleus in WT VSMCs (Fig 3.2 C), which coincides with our original
report (40). Using these isolated primary VSMCs, we assessed superoxide production
to Ang II, which initiates a VSMC signaling cascade to induce NOX catalytic activity, and
NAPDH, a direct ligand of NOX catalytic activity. We found that compared to WT, aortic
VMSCs from GPER KO animals displayed a near total abrogation of superoxide
formation to Ang II and NADPH stimulation, whereas pretreatment of WT VMSCs with
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NOX-inhibiting peptide gp91dstat reduced superoxide production to Ang II and NADPH
to levels of KO SMCS (Fig 3.3 A,B). To further corroborate these data, we employed
an additional measure of indirect superoxide detection using dihydroethidium (DHE).
Red fluorescence of DHE oxidized by superoxide was similarly diminished in GPER KO
VMSC compared to WT VSMCs when challenged with Ang II. Pretreatment of WT
VSMC with gp91dstat to inhibit NOX reduced DHE signal to levels seen in GPER KO
VSMCs (Fig 3.4 C). In either method of detection, we saw no differences in resting
ROS levels between WT and GPER KO VSMCs prior to stimulation with Ang II or
NADPH.
3.4.2 GPER deletion subsequently blunts calcium increase to Ang II in VSMCs.
A vital downstream intermediate of ROS-induced contraction is the increase of
intracellular calcium. Given that contraction in GPER KO aorta is reduced, and ROS
response to Ang II in GPER KO VMSCs is also reduced, we sought to confirm that
intracellular calcium was also reduced due to a decrease in ROS production in GPER
KO VSMCs. Calcium fluctuations were detected in live cells in real time by the
calcium-sensitive dye Indo 1 AM using a PTI spectrofluorimeter to measure the ratio of
calcium-bound to unbound Indo1 AM. Upon stimulation with Ang II (100 nM) the ratio of
calcium-bound to unbound Indo1 AM increased in WT, but this response was
significantly abrogated GPER KO VSMCs, indicating there was a lack of intracellular
calcium increase to Ang II, likely as a result of reduced ROS production to Ang II (Fig 3.
4). The loss of calcium response in WT cells was reduced by the NOX-inhibiting
peptide gp91ds-tat, indicating that a loss of ROS production was capable of reducing
the calcium response. The calcium response to purinergic receptor activation with ATP
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(an alternative, Ang II-independent pathway), was robust in both WT and GPER KO
VSMCs, indicating the loss of calcium increase in GPER KO VSMCs may be specific to
the Ang II and NOX signaling pathway(s). These data indicate that the loss of calcium
response in GPER KO VSMCs is likely in part due to a loss of ROS response to Ang II,
which also coincides with the reduced contraction response to Ang II seen in GPER KO
aorta.
3.4.3 Chronic, but not acute GPER inhibition reduces superoxide production to
Ang II in VSMCs. To elucidate a mechanism of GPER in regulating NOX-mediated
superoxide production, we designed an experiment to determine if the role of GPER
was in rapid activation and/or assembly of NOX subunits, or in genomic expression of
NOX subunits. To this end, we employed pharmacologic inhibition with GPER-specific
antagonist G36 at 100 nM for three days or 30 min in primary mouse WT VSMCs prior
to lucigenin detection of superoxide production to Ang II and NADPH stimulus. We
found that chronic, but not acute inhibition of GPER reduced superoxide production in
WT VSMCs to GPER KO levels (Fig 3.5).
3.4.4 GPER deletion results in decreased NOX1 and p22phox expression in
VSMCs. Given that GPER activity exerted long-term, genomic related changes in NOX
signaling, we assessed NOX subunit expression in WT and GPER KO VMSCs by
QPCR and Western blot. QPCR showed approximately 50% reduction in expression of
NOX1, the catalytic subunit and p22phox, the plasma membrane anchoring unit of
NOX1 in KO VSMCs compared to WT VSMCs. QPCR showed that there was a loss of
approximately half the expression of NOX1 and p22phox in GPER KO VSMC compared
to WT, and that RNA levels of other components of NOX and Ang II signaling were
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unaffected (Fig 3.6). We followed up RNA data by examining protein expression levels
by Western blotting and found that indeed, there was a reduction of approximately 55%
of NOX1 protein in GPER KO VSMCs compared to WT (n=4 per genotype,
p=0.027)(Fig 3.7).
3.4.5 GPER inhibition results in decreased superoxide production and NOX1
expression in human VSMCs. To confirm that our observations were not an anomaly
of the GPER KO mouse model, we sought to corroborate these data in VSMCs of
different species. In the immortalized rat aortic smooth muscle cell line A7r5 we found
that chronic (3 day), but not acute (30 min) inhibition of GPER also resulted in reduced
superoxide generation to Ang II and NADPH challenges via lucigenin detection (data
not shown). Critically, we established that in primary human aortic smooth muscle cells,
chronic (3 day) but not acute (30 min) inhibition of GPER using both pharmacologic
(G36) and genomic (siRNA) approaches resulted in a reduced superoxide response to
Ang II and NADPH (Fig 3.8 A,B). Furthermore, chronic inhibition of GPER in human
aortic VSMCs also resulted in decreased NOX1 protein expression (Fig 3.9). These
data infer that GPER signaling regulates NOX1 expression in human VSMCs, thereby
contributing to regulation of VSMC contraction to Ang II via NOX1 expression.
3.4.6 GPER deletion results in reduced expression of JunB, a vital mediator of
NOX1 expression. To hypothesize a mechanism of GPER regulation in NOX1
expression, we utilized previous reports demonstrating that the transcription factors
JunB and MEF2B were involved in upregulating NOX1 transcription in an AP-1
dependent manner (209) (210) (211, 212). Both expression and activation of JunB and
MEF2B in multiple cell types is mediated by ERK1/2 (213-215), which is a known
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secondary kinase messenger of GPER signaling via cross activation of EGFR. We
hypothesized that GPER- mediated ERK1/2 activation leads to increased JunB and
MEF2B expression, which in turn increases NOX1 transcription. QPCR of WT and
GPER KO VSMC revealed that JunB expression was decreased in KO VSMCs
compared to WT VSMCs (n=4 p<0.05) (Fig 3.10). Taken together, these data implicate
that GPER deletion results in decreased JunB expression, which may reduce NOX1
transcription and reduce ROS-mediated Ang II contractions in VSMC.
3.4.7 reintroduction of NOX1 restores superoxide response to Ang II in VSMCs of
GPER KO mice. We sought next to determine if reintroduction of NOX1 could restore
the superoxide response in GPER KO VSMCs. Constructs of Adenoviral NOX1 with
GFP or empty adenoviral vector with GFP were transfected into GPER KO VSMC, and
superoxide response to Ang II and NADPH we measured three days later. Indeed we
found that restoration of NOX1 by adenoviral transduction restored superoxide
production to Ang II in GPER KO VSMCs (Fig 3.11). There was no restoration of
superoxide signal by lucigenin in KO VSMCs transfected with GFP alone.
3.4.8 GPER inhibition or deletion reduces or blocks the hypertensive response to
Ang II in mice. To test the physiologic efficacy of our cellular studies, we employed a
rodent model of hypertensive challenge (Fig 3.12). We hypothesized that
pharmacologic inhibition (G36 infusion) or genomic deletion (GPER KO) of GPER would
abrogate hypertensive onset in response to Ang II challenge by reducing the NOX
mediated superoxide response and ROS accumulation resulting from RAS-mediated
hypertension. WT mice were fitted with a subcutaneous placebo pellet or G36releasing pellet (0.7mg/kg/day) for three days prior to insertion of a subcutaneous
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osmotic pump releasing Ang II peptide (0.7mg/kg/day) or PBS. GPER KO mice also
received a placebo pellet and Ang II or PBS osmotic pump. Systolic blood pressure
(SBP) was monitored by conscious tailcuff readings from three days prior to pellet
infusion up to two weeks post-insertion of osmotic Ang II pump. Mice were euthanized
after two weeks of Ang II treatment and their tissues were taken for molecular and
superoxide analysis, and vasoreactivity. In WT mice receiving placebo pellet and Ang
II pumps, SBP increased by 30 mm Hg, indicating a hypertensive response to Ang II. In
WT mice receiving G36 prior to Ang II pump infusion, this hypertensive onset was
partially abrogated by ~30 mm Hg. In GPER KO animals receiving Ang II osmotic
pumps, there was no hypertensive onset (Fig 3.13). Taken together, these data indicate
that GPER is significant in mediating the hypertensive onset to Ang II in a mouse model.
3.4.9 GPER inhibition reduces superoxide production to Ang II in aortic rings of
mice. To determine if this diminished hypertensive response was due to a lack of
superoxide production to Ang II, superoxide levels in aortic rings from each treatment
group were measured by lucigenin and DHE. Both methods of ROS measurement
showed reduced superoxide levels in aortic rings from GPER KO animals and WT
animals receiving pharmacologic inhibition of GPER prior to Ang II hypertensive
challenge (Fig 3.14). We made the critical observation that there was no significant
difference in ROS levels (as detected by DHE) between GPER KO and WT animals
receiving PBS pumps, implicating that GPER deletion protects from Ang II hypertension
by abating the ROS response.
3.4.10 GPER inhibition or deletion reduces NOX1 expression in aortic rings of
mice. Levels of NOX1 protein were measure by immunofluorescence in mouse aortic
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rings from different treatment groups. Confocal microscopy of FITC-labeled NOX1 in
aortic rings indicated elevated NOX1 protein expression in rings from WT animals
receiving placebo pellet and Ang II osmotic pump. Conversely, we saw reduced NOX1
expression in aortic rings from GPER KO animals and WT animals infused with GPER
specific antagonist G36 prior to Ang II challenge (Fig 3.15). The data from this animal
study demonstrate a mechanism whereby inhibition of GPER prevents hypertensive
onset by Ang II by mitigating superoxide production through genomic inhibition of
NOX1.
3.5 CONCLUSIONS AND DISCUSSION:
Our data demonstrate that GPER regulates NOX1 expression (but not acute
activation) in vascular smooth muscle, thereby indirectly regulating superoxide
production to Ang II. This genomic regulation may be mediated by GPER activation of
ERK1/2 to mediate JunB expression, which in turn promotes NOX1 expression in
vascular smooth muscle cells of multiple species (Fig 3.16).
A critical conclusion of this report is that GPER activity was required for the
physiologic hypertension response to Ang II challenge in mice. Hypertension onset
due to increased activity of the renin-angiotensin aldosterone system (RAAS) is
commonly observed in the clinic. To this end, multiple successful drugs employed to
counter hypertension in the clinic are inhibitors of the RAS, such as ACE 2 and renin
blockers (blocking the generation of Ang II peptide) or angiotensin receptor blockers
(blocking the signal transduction of Ang II in cells) (216-219). Our data suggest that
another feasible route of hypertension treatment may be the reduction of NOX1
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expression via pharmacologic inhibition of GPER, which will to reduce the NOX
superoxide response to Ang II, and abrogate hypertension.
The NOX blocking peptide gp91dstat was originally reported by the Pagano
laboratory in 2011 (University of Pittsburgh) as effective in blocking NOX formation and
catalytic activity to prevent superoxide formation (198). We utilized this peptide in to
mimic the loss of contraction and superoxide accumulation in WT aorta and VSMCs
seen in GPER KO smooth muscle, and to demonstrate that loss of GPER recapitulates
the loss of superoxide seen when NOX is inhibited. The gp91ds -tat peptide prevents
NOX activation by blocking the interaction of the scaffolding p22phox subunit with the B
loop of the NOX catalytic subunit at the plasma membrane. This peptide was originally
tested for preventing superoxide accumulation in cell-free systems and HEK 293 cells
transduced to overexpress different NOX isoforms (NOX1,2,4). Although gp91dstat has
been described as NOX 2-specific (198), the conservation of the B-loop docking site
between NOX isoforms (220) brings into question the specificity of gp91ds-tat targeting,
thus the specificity of the peptide is debated in the literature (221). Our data here
indicate that the peptide blocks superoxide response in SMCs, of which NOX1 is the
primary isoform. Given that our studies were performed in isolated smooth muscle
cultures, and that the pathway we tested in ROS development (Ang II) is an
endothelium- independent, we suspect that the gp91dstat peptide inhibited NOX1
activity in our experiments.
We demonstrate here that GPER contributes to NOX-mediated superoxide
production in response to Ang II and NADPH, and it followed that inhibition of GPER
abrogated increases in systolic pressure associated with Ang II infusion by reducing
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superoxide production in response to Ang II peptide. We and others have reported that
GPER-specific agonist G-1 promotes vasorelaxation through eNOS activation and
reduction of oxidative damage (54, 71, 107, 126, 208). However, there are several
conflicting reports where G-1 infusion did not prevent hypertension (130). Given the
reported findings of White et al. (105), we hypothesized that overproduction of ROS by
the Ang II infusion model may promote NO scavenging into peroxynitrate radical
(ONOO-). This ROS-enriched environment can decouple tetrhydrobiopterin and eNOS,
and lead to even greater augmentation of ROS that will be further stimulated by
constitutive activation of uncoupled eNOS by G-1. We therefore reasoned that GPER
agonist (G-1) infusion may have only moderate or early effects in abrogating
hypertension, and that these effects would be lost at later time points due to ROS
saturation from Ang II infusion and eventual eNOS uncoupling, which will magnify ROS
accumulation. Studies by Lindsey et al. employing G-1 to prevent a salt induced
hypertension in mRen2 rats showed reduced oxidative stress and proteinuria in the
kidney, but no protection from hypertension (151). While these studies indicate that G-1
likely decreased ROS at the kidney by increasing eNOS activity, we propose that the
persistence of hypertension may stem from GPER-mediated NOX1 expression
increases resulting in ROS accumulation.
In perspective, this study is significant and progressive in several aspects. First, it
implicated a novel mechanism by which estrogen contributes to ROS production in
healthy vascular function. This finding has implications on the divergent effects
estrogen replacement therapy has had on cardiovascular function and stroke, as
evidenced by the deleterious outcome of estrogen replacement in the Women’s Health
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Initiative in the 1990s (143). We propose here a mechanism by which estrogen
replacement in post-menopausal women may conversely increase ROS production.
This scenario is further supported by the notion that post menopausal endothelium is
dysfunctional and has lower basal NO levels and uncoupled eNOS, thereby
compounding ROS accumulation. ROS accumulation can occur both through
hyperactivation of NOX activity and by increasing NOX expression to sustain ROS
production in the smooth muscle. The data we report here may suggest that estrogen
replacement therapy could be supplemented with GPER-specific antagonist G36 to
reduce vascular oxidative stress in E2 replacement as a possible therapeutic.
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Fig 3.1
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Fig3.1 GPER is required for angiotensin II-induced, Nox-mediated contraction.
Contractile responses to Ang II are reduced in GPER-deficient thoracic aorta. The
NADPH oxidase inhibitor gp91ds-tat (gp) acutely decreases contraction to Ang II only in
WT arteries (A). Contraction in response to KPSS is unaltered by GPER deficiency (B).
n=4-5/group, *p<0.05 vs. untreated, †p<0.05 vs. WT. This data was borrowed with
permission from Matthias Meyer, MD as preliminary data to this dissertation.
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Fig 3.3
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Fig. 3.3 GPER deficiency markedly
reduces Nox activity and abolishes
angiotensin II-induced, Nox-dependent
superoxide
formation:
NADPHstimulated superoxide production was
markedly reduced in GPER-deficient
VSMC (A). Ang II (in the absence of
exogenous NADPH) produced a small
amount of superoxide in WT cells, which
is abolished by the Nox-inhibitor gp91dstat and deletion of GPER (B).
Luminescence units were normalized to
VSMC count. n=3-5/group, *p<0.05,
**p<0.01 vs.WT. C) Detection of
superoxide with DHE also indicated a
significant
reduction in
superoxide
response to Ang II in GPER Ko VSMCs
compared to WT. NOX inhibition reduced
Ang II induced superoxide production in
WT VSMCs to levels of GPER KO.

Fig 3.4

GPER KO

#
GPER KO
GPER KO
Fig 3.4 GPER KO VSMCs exhibit decreased intracellular calcium response to Ang II:
Superoxide increase results in calcium increases in VSMCs. Indo1 AM detection of free
intracellular calcium revealed that GPER KO VSMCs had decreased intracellular calcium
response to Ang II compared to WT, and that inhibition of NOX using gp91dstat in WT VSMCs
reduced intracellular calcium responses to levels observed in GPER KO VSMCs. ATP induced
intracellular calcium increases in both WT and GPER KO VSMCs, indicating the abrogated
calcium response to Ang II is likely pathway specific. A) Raw trace of bound to unbound
Indo1AM ratios in WT and GPER KO VSMCs. B) quantitative summary of raw traces. C)
Quantitative summary of ATP-induced
#p<0.05 vs. WT control,*P<0.05 vs. w/o gp
intracellular calcium increase.
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Fig 3.5

Fig 3.5 Chronic but not acute GPER inhibition reduces the superoxide response to
Ang II in WT VSMCs: WT VSMCs in p.3-4 were cultured for 3 days (72h) in 100 nM G3 or
vehicle (0.01%DMSO) and treated with G36 (100 nM) 30 min prior to harvest for lucigenin
detection of superoxide response to Ang II. As a negative control, some cells were
prereated with 3 uM gp91dstat to inhibit NOX signaling for 30 min prior to lucigenin
experiments. 72 hour, but not 30 min of G36 pretreatment reduced superoxide response
To vehicle levels. To compare, 30 min of NOX inhibiting peptide also fully reduced the
superoxide response to Ang II in WT VSMCs. *P<0.05 vs. WT, # P<0.05 vs. veh, n=4-6 per
treatment
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Fig 3.6
GPER KO

Fig 3.6 GPER regulates Nox1 and p22phox gene expression in VSMC: Deletion of the
GPER gene markedly reduces Nox1 and p22phox gene expression, which may explain the
lack of superoxide production and arterial contraction. n=6/group, **p<0.01 vs. WT.
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Fig 3.8
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Fig 3.8 Chronic but not acute inhibition of GPER results in reduced ROS production to
Ang II: A) Aortic smooth muscle cells from rat A7r5, and primary human aortic smooth muscle
cells were treated for three days or 30 min with 100 nM G36 prior to harvest for lucigenin
detection of ROS production to Ang II. In some instances cells were treated with NOX inhibitor
gp91dstat as a control for ROS inhibition. Chronic inhibition of GPER with 3 days (changed
every 24 h) but not 30 min reduced superoxide response to Ang II in aortic SMCs from all
species. B) genomic inhibition of GPER with siRNA also reduced ROS response to Ang II.

*p<0.01 vs. WT
Data shown above for human aortic SMC only
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Fig 3.9

Fig 3.9 Chronic GPER inhibition reduces NOX 1 protein in human VSMCs: Human aortic VSMCs
were treated with GPER-specific antagonist G36 (100 nM) or vehicle (0.01% DMSO) for three days
and lysed for total protein and blotted for total NOX 1 protein expression. VSMCs treated with
G36 had a reduction in NOX 1 protein levels of approximately 40%.
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Fig 3.11
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Fig 3.11 reintroduction of NOX 1 restores ROS response to Ang II in GPER KO VSMCs:
GPER KO VSMCs were transduced with Adenoviral constructs of GFP-labeled NOX 1 or empty
GFP vector. Viral expression of NOX 1 GFP reestablished the superoxide Response to Ang II in
GPER KO VSMCs, but adenoviral GFP alone did not. TL= transmitted light
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Fig 3.12
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Fig 3.12 Experimental design of mouse hypertension: Mice were trained for one week to sit
calmly for conscious tailcuff readings of systolic blood pressure (SBP), and then a baseline SBP
reading was taken for three days. After baseline SBP was established, mice were given a
subcutaneous pellet releasing G36 or placebo pellet at the left hind leg, and were allowed to
recover for three days while still receiving SBP readings. Mice were then fitted with an osmotic
pump releasing Ang II or PBS at the intrascapular region. SPB readings were taken for two
weeks following osmotic pump insertions. At two weeks, animals were euthanized and their
tissues were harvested to assess ROS accumulation and for additional molecular analysis.
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Fig 3.13
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Fig 3.13 GPER deletion and inhibition reduces hypertension response to Ang II
infusion in mice: A) WT mice receiving subcutaneous pellets releasing GPERspecific inhibitor G36 (diamonds) had an abrogated hypertension response to Ang II
infusion by osmotic pump compared to mice with placebo pellet (circles). B) GPER KO
mice did not exhibit hypertensive onset to Ang II infusion (black squares).
*p < 0.05 vs. veh, #p< 0.05 vs. WT AngII
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Fig 3.14
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Fig 3.14 Loss of GPER reduces superoxide deposition in aorta of mice receiving
Ang II hypertensive challenge: Thoracic aorta slices fro mice treated with G36 or
placebo or Ang II or PBS vehicle osmotic pumps were treated with DHE to detect
superoxide levels. Thoracic aorta from mice treated with GPER specific antagonist
G36 had reduced superoxide compared to thoracic aorta from WT animals that
received Ang II infusion and became hypertensive. Thoracic aorta from GPER KO
animals receiving Ang II did not show an increase in superoxide. Compared to
negative controls (PBS pump). N=4-5animals per group, 5 aorta slices per animal.
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Fig 3.15
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Fig 3.15 GPER inhibition reduces NOX 1 levels in a model of Ang II hypertension:
WT,GPER KO mice and WT mice receiving GPER antagonist G36 were challenged for two
weeks with Ang II osmotic pump and their aortas were harvested and stained for NOX 1
protein expression. WT animals treated with Ang II had increased NOX 1 expression, while
WT animals receiving both GPER antagonist G36 and Ang II had a reduction in NOX 1
expression compared to WT placebo. Thoracic aorta from GPER KO mice receiving Ang II did
not exhibit an increase in NOX 1 protein. NOX 1 basal expression was no different between
WT and GPER KO animals receiving vehicle (PBS) infusion. N=4 animals per group, 3-4
slices per animal.
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Fig 3.16
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Fig 3.16 Summary: GPER mediates chronic NOX 1 expression, but not acute activation.
GPER may mediate NOX 1 expression through ERK1/2 activation to induce JunB expression
and activation, which regulates transcriptional activation of NOX 1.
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CHAPTER FOUR:
CONCLUSIONS AND FUTURE DIRECTIONS
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4.1 Overall Discussion and Future Directions:
The complex role of estrogen in vascular function is not yet fully understood.
While E2 has been shown to acutely increase vascular dilation through eNOS activation
and increase eNOS expression (98, 222), studies of chronic E2 treatment both in
research animals and in the clinic yield mixed results regarding blood pressure effects
(223) (224) (143) (225) (128). It has been shown that the G protein-coupled estrogen
receptor, GPER, also mediates the vasoprotective effects of estrogen (128, 130), and is
likely needed in collaboration with signaling from ERα for eNOS activation and NO
production. Furthermore, a role of GPER in mediating vasoprotective effects of SERMS
and SERDs has not yet been characterized in the vasculature. Furthermore, the effects
GPER may have in vascular smooth muscle regulation of vascular reactivity are
unclear. To address these gaps in knowledge, we sought to elucidate the contribution
and mechanism(s) of GPER in regulating eNOS activation in endothelial cells, and to
characterize the role of GPER signaling in vascular smooth muscle cell contraction.
Utilizing a telomerase immortalized endothelial cell line (TIVE), we demonstrated
that the GPER-specific agonist G-1 stimulates eNOS activation through downstream
phosphorylation of ser1179, resulting in nitric oxide (NO) production. When GPER was
inhibited using the GPER-selective antagonist G36 and siRNA targeting GPER, there
was a decrease in NO production in response to E2, but not to acetylcholine,
suggesting that GPER is necessary to mediate the full effects of E2 on eNOS activation,
but is not necessary for eNOS activation in response to other (non-estrogenic)
vasodilators. The contributing role of GPER in E2-mediated vasorelaxation was
confirmed with myography experiments on mouse thoracic aorta. Vasorelaxation to E2
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in thoracic aorta from GPER KO mice was reduced by ~50% compared to wild type.
Importantly, there was no reduction in acetylcholine-mediated vasorelaxation in GPER
KO aorta compared to wild type, indicating that GPER is involved specifically in the E2mediated mechanism of eNOS-dependent vasorelaxation, but is not involved in
downstream eNOS-mediated vasorelaxation. Inhibition of EGFR and PI3K/AKT
reduced NO production to both E2 and G-1, implicating these intermediate signaling
kinases in E2-mediated eNOS activation. Additionally, inhibition of other known
signaling kinases, including c-Src and ERK1/2 also reduced NO production in response
to E2 and G-1, indicating roles for these kinases in ERα- and GPER-mediated
vasodilation. It is likely that ERα and GPER are capable of regulating eNOS at multiple
residues in addition to ser1179, such as c-Src-mediated phosphorylation of the
activating residue Y81 and ERK1/2-mediated dephosphorylation of the inhibitory
residues Thr 495/617 (226, 227) (228).
Given that the SERMs tamoxifen and raloxifene as well as the SERD ICI182,780
have been shown to signal through GPER in multiple cell types (68, 74), we postulated
that GPER may be responsible for mediating vasorelaxation in response to these
SERMs through eNOS activation. Indeed, when we measured NO production in
response to these “anti-estrogens” in TIVE cells, the generation of NO in response to
ICI182,780 and tamoxifen was reduced by approximately 35% in TIVEs pretreated with
GPER antagonist G36. Although significant, these results leave open the possibility
that additional (non-GPER-mediated) mechanisms are involved in the NO response to
these compounds.
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From the data presented in Aim 1 (Chapter 2), we conclude that GPER indeed
contributes to estrogenic activation of eNOS for NO production, and that inhibition of
GPER reduces NO production to E2 as well as to SERMs and SERDs. As inhibition of
GPER by pharmacologic antagonism (G36) or global deletion (GPER KO) reduces NO
production and vasorelaxation to E2 and SERMs/SERDs, it follows that GPER signaling
is responsible for partially contributing to the entirety of the E2 response of eNOS. We
also conclude that GPER mediates eNOS activity acutely but does not modify long-term
eNOS expression as ERα does. We demonstrated that the signaling pathway(s)
involved in GPER-mediated eNOS activation are dependent on transactivation of the
EGFR and PI3K/AKT signaling pathway, as well as through parallel pathways of
ERK1/2 and c-Src activation, which modify additional regulatory residues on eNOS.
Therefore, GPER plays a pivotal role in mediating the vasoprotective effects of estrogen
by contributing to eNOS activation.
Future directions for Aim 1 include additional characterization of GPER signaling
pathways for the different eNOS regulatory residues such as the activating residue
Tyr81 and the inhibitory residues Thr495 and Ser617 and 116. Inhibition of c-Src and
ERK1/2 showed decreased NO production to both E2 and G-1, which suggests that
estrogen receptor mediated eNOS activation may occur through multiple pathways in
addition to EGFR and PI3K/AKT activation, which is a novel finding of this study
meriting further investigation.
We also presented the interesting observation that GPER inhibition is unable to
fully block NO production to SERMs and SERDs. As the SERMs tamoxifen and the
SERD ICI 182,780 are known to have antagonistic actions against classic ERs, our data
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implicate that these compound may have ER-independent signaling pathways, at least
in endothelial cells, that result in increased NO production. This characterization of
SERMs in endothelial function here postulates the critical consideration that SERMs
and SERDs, while usually only thought of in the narrow aspect of ER signaling
modifications, must be considered more broadly for their cross-activity effects in cell
signaling independent of ER signaling. Such insights open the discussion for
considering ER-independent effects in future SERM/SERD studies both in basic
research and in the clinic.
Given that the effects of GPER on vascular smooth muscle contraction are less
known, we sought to characterize the contributions of GPER to vascular smooth muscle
function by examining contraction to Ang II in arteries from GPER KO mice. Since it is
known that GPER contributes to NO production, we hypothesized that arteries from
GPER KO animals would exhibit greater contraction to Ang II due to a partial loss of
vascular eNOS activity in GPER KO animals. Surprisingly, we observed that the
arteries of GPER KO mice exhibited reduced contraction in response to Ang II
compared to wild type arteries. We were able to mimic this loss of contraction (in KO
arteries) in WT arteries using the NOX peptide inhibitor gp91dstat. Importantly, there
was no additive effect of NOX inhibition in GPER KO arteries, suggesting that the
decreased contraction to Ang II in GPER KO arteries was moderated through a
decrease in (i.e. loss of) NOX activity. VSMCs isolated from GPER KO mice exhibited a
dramatic decrease in superoxide production in response to Ang II and NADPH
compared to WT. Chronic (3 day, employing 100 nM G36 or siRNA), but not acute (30
min treatment with 100 nM G36) inhibition of GPER in (WT) mouse, rat, and human
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aortic SMCs recapitulated the abrogated superoxide response observed in GPER KO
VSMCs. Furthermore, GPER KO SMCs as well as WT mouse, rat and human AoSMCs
treated for 3 days with the GPER antagonist G36 exhibited a reduction in NOX1 RNA
and protein expression that coincided with reduced superoxide responses to Ang II and
NADPH. These data suggest that GPER regulates superoxide production by controlling
expression of NOX1 in VSMCs.
We next sought to resolve if pharmacologic targeting of GPER using the GPER
antagonist G36 could abrogate a hypertensive challenge of Ang II infusion in mice by
reducing the superoxide-mediated component of hypertension. Mice were fitted with
G36-releasing pellets (0.7 mg/day) or placebo 3 days prior to insertion of an Ang IIcontaining osmotic pump (0.7mg/day), and systolic blood pressure was measured by
conscious tailcuff for two weeks. In agreement with our cellular and ex vivo results,
mice pretreated with the GPER-selective antagonist G36 exhibited reduced
hypertensive response to Ang II infusion compared to mice pretreated on placebo.
Surprisingly, GPER KO animals receiving Ang II infusion were completely resistant to
hypertensive effects of Ang II.
Taken together, data from specific aim 2 (Chapter 3) present a novel paradigm of
GPER signaling where superoxide production is modulated by GPER-mediated
regulation of NOX1 expression. These data present a surprising and conflicting role of
GPER in the vasculature, since it had already been established that GPER contributes
to endothelial NO production involved in vasodilation, and we now present here that
GPER is also responsible for a ROS-mediated mechanism of contraction in vascular
smooth muscle. However, we postulate that GPER inhibition may be more
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advantageous to treat hypertension onset by blocking ROS accumulation, as current
studies of GPER activation with GPER agonist G-1 show mixed results (depending on
the estrogen levels in female mice) in preventing hypertension. We suspect that the
varied results of G-1 treatment in animal models of hypertension may have been
complicated due to increased GPER activity in the smooth muscle, which may have
lead to increased NOX1 expression, possibly resulting in increasing ROS production
that may have been counteracting the GPER activation and NO production at the
endothelium.
Future directions of specific aim 2 will address the characterization of this novel
finding in other cardiovascular tissues such as the heart and kidney. Deleterious
effects of ROS in the kidney and heart contribute to major aspects of CVD, such as
decreased kidney function, cardiac fibrosis, ventricular remodeling and hypertrophy.
Evaluating the role of GPER in regulating NOX expression and subsequent ROS
production in these tissues may identify a robust mechanism of ROS regulation. These
findings implicate GPER as a possible therapeutic target for treating ROS-related CVD
in multiple cardiovascular tissues.
Further investigation of the specific mechanisms responsible for GPER regulation
of NOX1 expression is needed to fully understand the role of GPER in smooth muscle
ROS. Two transcription factors known to mediate NOX1 expression are JunB and
MEF2B, which activate the transcription factor AP-2 for binding at the NOX1 promoter
site (210). MEF2B and JunB gene expression is regulated by ERK1/2, which is a
known secondary messenger of GPER. QPCR of GPER KO and WT VSMCs show that
GPER KO VSMC have reduced JunB expression compared to WT. This data suggests
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an indirect mechanism of NOX1 downregulation by GPER, possibly through ERK1/2
activation of JunB transcription. It has also been shown that the NOX1 promoter region
contains estrogen response elements, suggesting a regulatory role for ERα, however,
additional NOX1 promoter elements that may be responsive to GPER activation are
unknown.
Accumulation of ROS in vascular tissues occurs naturally during the aging
process. Reports show that ROS production in tissues of the cardiovascular system
also contributes to CVD such as hypertension, inflammation, atherosclerosis and
cardiac fibrosis (229). Characterization of ROS production in the cardiovascular tissues
of aged GPER KO and WT animals may implicate a role for GPER in long-term ROS
regulation in aging cardiovascular tissue.
Conclusions from specific aim 2 (chapter 3) implicate the novel prospective that
an estrogen receptor (GPER) could be playing a larger role in vascular ROS, and
encourages investigations into additional cardiovascular tissues to determine if GPERmediated ROS plays a larger role in cardiovascular dysfunction.
4.2 Overall Conclusions and Perspectives:
This thesis has outlined several seminal findings in the GPER-mediated
regulation of endothelial and smooth muscle signaling in the vasculature. Our data
present a counterintuitive paradigm in which GPER is necessary for mediating the
estrogenic activation of eNOS in NO production, yet in contrast also contributes to
mediating superoxide production through genomic control of NOX1 in vascular smooth
muscle. Such a paradigm has been demonstrated in physiology before, such as the
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classical example of the effects of vasopeptide endothelin-1 (ET-1) which induced
vasorelaxation through calcium increase in endothelial cells (promoting calciumdependent eNOS activation) and contraction smooth muscle cells (promoting calciummediated activation of the contractile apparatus). Given such an interesting
juxtaposition of the GPER mechanism, the balance of an individual's cardiovascular
health (especially whether an individual has a healthy endothelium), age, and genetics
play a vital role in the global effects that pharmacologic alteration of GPER signaling
with have in their cardiovascular function. For example, while GPER activation (G-1)
may have positive effects in healthy, pre-menopausal women with a functioning
endothelium by contributing to NO production, an individual with endothelial dysfunction
due to aging or underlying CVD may actually benefit from GPER inhibition (G36) to
reduce oxidative stress in lieu of reduced NO benefits GPER may be able to provide in
such conditions.
These data provide crucial insights into the etiology of estrogen in hypertension.
The development of effective hormone replacement therapy (which commonly utilize E2
supplementation) to combat CVD in post-menopausal women is a significant issue in
the clinic. Given the findings of this thesis, an interesting approach could be to
supplement E2 replacement with the GPER-specific antagonist G36 to reduce the
extent of ROS production that may occur with E2 replacement through GPER activation.
Such clinical implications support further study of GPER in the cardiovascular system.
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